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SUMMARY 
Asthma bronchiale and chronic obstructive pulmonary disease (COPD) are two of the leading 
chronic respiratory diseases worldwide and associated with high morbidity, mortality, and a 
major economic burden. Despite progress in pharmacological and non-pharmacological 
treatment in recent years, the burden of disease among asthma and COPD patients is high. 
Reasons for uncontrolled diseases are manifold, but are often associated with poor 
inhalation technique and non-adherence to the prescribed treatment plan. As observed in 
many chronic diseases, poor adherence to medication is also a common phenomenon 
among asthma and COPD patients. This causes deterioration of symptoms and recurrent 
exacerbations resulting in increased rates of morbidity, physician visits, hospitalizations, 
mortality, reduced quality of life, and increased healthcare expenditures. However, it has 
been demonstrated that the frequency of exacerbation can be reduced by the administration 
of certain medication. Furthermore, high adherence is associated with reduced exacerbation 
rates in patients with asthma and COPD.  
As outlined above, maintaining adequate adherence to inhaled medication is of major 
importance for achieving therapeutic success, in particular for the treatment of chronic 
diseases. Different interventions and strategies are already described in the literature aiming 
to enhance adherence. The greatest success was attained with complex interventions 
combining several strategies. Nevertheless, to date no intervention was determined to be 
particularly successful. 
Therefore, this thesis aims to contribute to this challenging but important research field by 
investigating the impact of two simple interventions on adherence to inhaled therapy in 
patients with asthma and COPD.  
Prior to the study start, we provided a training course for each participant regardless of the 
treatment group to guarantee a comparable level of disease knowledge and inhalation 
technique. Further, each patient was equipped with an electronic monitoring device, which 
was used as the method of choice for the assessment of objective adherence. Overall, the 
performed intervention consisted of a reminder in form of phone calls and a daily alarm clock 
as well as feedback on patients’ individual adherence profile. The combination of these two 
common types of interventions has been chosen since they appeared to be easily applicable 
in daily clinical practice. We considered this to be one of the important factors in order to 
guarantee an efficient improvement of patients’ adherence.  
By the intervention, we expected a prolongation of time to next exacerbation, which was 
defined as the primary endpoint of this study. Moreover, we assumed an improvement of 
patients’ taking and timing adherence as well as quality of life, determined as the two 
secondary endpoints. 
The thesis is divided into the following three parts: 
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The aim of Part I was to design and write a study protocol taking into account the above-
mentioned aims and under consideration of the current state of the literature as well as the 
studies already conducted in this field. 
Part II describes a cross-sectional analysis to evaluate baseline data on compliance in 
accordance with current treatment guidelines (Global Initiative for Asthma (GINA) and Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines). Furthermore, baseline 
data is provided on inhaler application after a training course and its impact on quality of life 
and symptom control in a typical population with chronic lung diseases from the Adherence-
Trial. Overall, correct inhalation technique ranged from 55% to 100% depending on the type 
of inhaler. 112 participants (68%) participants were treated corresponding to the global 
guidelines. COPD patients with incorrect device application had a higher CAT sum score 
compared to those with a correct device application (p=.02). Moreover, COPD patients with 
incorrect device application had to cough more often (p=.03) and were more breathless while 
walking up hills or one flight of stairs (p=.02). While there was no significance to be found in 
asthma patients, COPD patients who used their devices correctly had a significantly better 
mean FEV1% predicted at baseline compared to those who applied their devices incorrectly 
(p=.04).  
In the last part of this thesis (Part III), time to next exacerbation - the primary endpoint of the 
study - was evaluated and compared between the intervention and the control group. 
Furthermore, the objective adherence was analyzed by evaluating the taking and timing 
adherence, as well as the gaps during the study period. Patients’ quality of life was assessed 
by the St. George Respiratory Questionnaire (SGRQ). Time to next exacerbation was longer 
(172 days [95% CI, 161 to 182] vs. 161 days [95% CI, 149 to 174], p=.27) and the risk for 
experiencing an exacerbation lower (HR, 0.67 [95% CI, 0.36 to 1.33], p=.14) in the 
intervention compared to the control group, but failed to reach statistical significance. In the 
intervention group significantly more days with a taking adherence between 80-100% were 
observed with both inhalation techniques (puff inhalers: 81.6±14.2 vs.60.1±30.3, p<0.001; 
dry powder capsules: 89.6±.9.8 vs. 80.2±21.3, p=.01). Timing adherence with regard to the 
use of puff inhalers was significantly higher in the intervention compared to the control group 
(68.9±25.0 vs. 50.6±32.5, p<.001) while there was a trend towards improved timing 
adherence for dry powder capsules (79.6±12.6 vs. 71.7±22.0, p=.052). However, no effects 
on health-related quality of life were observed (p>.05). 
In conclusion this thesis showed:  
• At baseline, a large number of the participating asthma, COPD or asthma-COPD 
overlap patients were treated on target based on the GINA and GOLD guidelines 
valid at the time of the patient’s inclusion into the Adherence-Trial. 
 
• Correct handling of inhaler devices was largely dependent on the device used. In the 
Adherence-Trial population, metered dose inhalers were applied more frequently in 
an incorrect way compared to dry powder inhalers. This particularly applies to the 
Ellipta® device, which has just recently been introduced to the market and which 
showed a very good applicability. 
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• A correct inhalation technique of the prescribed medication had a positive impact on 
the health status and the lung function of COPD patients. This was achieved by a 
comprehensive training of correct inhalation technique.  
 
• Regular, automatic and personal reminders seem to have caused a significant 
improvement in taking and timing adherence with regard to the inhalation with puff 
inhalers and dry powder capsules. Moreover, reminders can help to avoid forgetting 
the inhalation of the prescribed medication. Patients who experienced support in their 
adherence had significantly fewer days without inhalation and fewer gaps over 
several consecutive days compared to patients receiving no support. 
 
• Regular, automatic and personal reminders, led to a substantial improvement in 
patients’ adherence to inhaled medication. However, this was not associated with an 
improvement in health-related quality of life in patients with chronic airway diseases. 
 
• Higher adherence to the prescribed medication plan was not only associated with a 
trend towards longer time to next exacerbation but also with a reduced risk of 
experiencing an exacerbation.  
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GENERAL INTRODUCTION 
Respiratory diseases represent a huge and continuously increasing challenge to the national 
and international healthcare systems. Especially patients suffering from chronic respiratory 
diseases such as asthma or Chronic Obstructive Pulmonary Disease (COPD) tend to have 
severe symptoms due to exacerbations, which often require emergency room visits or 
hospital admissions [1].  
ASTHMA BRONCHIALE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
According to the Global Initiative for Asthma (GINA), asthma bronchiale is defined as ”a 
heterogeneous disease, characterized by a chronic airway inflammation and a history of 
respiratory symptoms such as wheezing, shortness of breath, chest tightness and cough that 
vary over time and in intensity, together with variable expiratory airflow limitation” [2]. In 
contrast, COPD is defined as a common, preventable and treatable respiratory disease, 
marked by persistent airflow limitation, which is usually progressive and associated with an 
inflammatory response of the lung to gases or noxious particles [3]. Both asthma and COPD 
are highly prevalent and represent two of the leading causes of morbidity, mortality and 
economic burden worldwide [1]. In 2011, the total direct healthcare costs in Switzerland for 
asthma patients ranged between 776 Mio. CHF and 1’443 Mio. CHF [4-6] while the total 
costs for the treatment of COPD patients were estimated to be between 603 Mio. CHF and 
3’234 Mio. CHF [6-8]. The variability in costs can be explained by very patient-specific 
treatments required, resulting in different cost estimates per patient [6]. Globally, it is 
assumed that 235 million people suffer from asthma [9] and 65 million have a moderate-to-
severe COPD diagnosis [1]. Moreover, the prevalence of asthma and COPD is continuously 
increasing. The prevalence of asthma is particularly rising in the Western world, due to 
growing urbanization of communities and increase in atopic sensitization [10, 11]. However, 
the rise in COPD diagnosis is mainly caused by an ageing population and an increase in 
smoking exposure [12]. According to the World Health Organization (WHO), COPD currently 
represents the fourth leading cause of death worldwide and is predicted to become the third 
leading cause of death by 2030 [13]. 
For both, asthma and COPD, effective therapy options are available. Treatments for chronic 
respiratory diseases are mostly administered directly into the respiratory tract by inhalation 
devices. Nonetheless, the everyday use of such inhaler devices poses several challenges 
with regard to the patient’s regular medication inhalation. The most patients consider the 
utilization of available inhalation devices such as metered dose inhalers (MDI), dry powder 
inhalers (PDI) or nebulizer as difficult because of the multiple application steps [14]. 
Moreover, pharmacological therapies for asthma and COPD are often long-term treatments 
requiring combinations of several drugs. The most commonly prescribed types are controller 
medication, which is used for a daily maintenance treatment and reliever (rescue) medication 
providing alleviation of breakthrough symptoms. The latter is also used during exacerbation 
and as short-term prevention during exercise-induced bronchoconstriction [2, 3]. The 
frequent seasonal occurrence of respiratory symptoms in asthma patients constitutes an 
additional complication with respect to medication adherence caused by the flexible dosage 
prescriptions in the self-management plans [2, 15]. Consequently, the complex drug 
combinations in the therapy plans represent a particular challenge for the affected patients 
due to varying inhalation times and different devices required.  
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According to the WHO, adherence is defined as “the extent to which a person’s behavior- 
taking medication, following a diet, and/or executing lifestyle changes corresponds with 
agreed recommendations from a healthcare provider” [16]. As observed for many chronic 
diseases [16], adherence to inhaled medication is generally poor in asthma and COPD 
patients. However, all prescribed treatment plans require sufficient long-term adherence. A 
systematic review summarizing the results of randomized controlled trials (RCT) 
demonstrated that adherence to long-term therapy is estimated to be around 50% [17]. 
Among asthma patients, rates of non-adherence range from 30% to 70% [18]. Levels of non-
adherence are comparably high in COPD patients, varying from 43% to 58% [19, 20]. Non-
adherence to prescribed treatment plans can lead to worse disease control and frequent 
exacerbations. Moreover, the quality of life of these patients is poor and medical care is used 
more often due to deterioration of symptoms and exacerbations. The latter aspect represents 
one of the main reasons for the associated costs of both chronic respiratory diseases [21-
25].  
MEDICATION ADHERENCE 
Medication adherence represents the basis for effective drug therapy and optimal disease 
control, particularly in chronic diseases such as asthma, COPD, arterial hypertension or 
diabetes mellitus. Despite the fact that adherence has been and continues to be the subject 
of numerous publications, factors affecting adherence, respectively non-adherence remain 
poorly understood.  
Adherence should be considered as a complex multidimensional issue with several 
influencing factors. According to WHO, these factors may be classified into the following five 
dimensions [16]: 
• Socioeconomic-related factors: financial situation, cultural background, illiteracy, 
age, distance to the physician. 
• Healthcare team and system-related factors: patient/healthcare professional-
relationship, medication distribution, duration of consultation, electronic information –
technology.  
• Condition-related factors: severity of symptoms, psychological strain, progression 
rate, comorbidities and availability of effective therapies. 
• Therapy-related factors: complexity of the medical regime, duration of treatment, 
previous treatment failures, side effects, frequent changes in treatment. 
• Patient-related factors: knowledge about disease, attitudes, beliefs, perceptions, 
expectations and mental or physical impairments of the patient. 
Patient-related factors should not be made solely responsible for non-adherence behaviour, 
since all of the above-mentioned factors may influence adherence. In fact, adherence 
represents a challenge for every patient and therefore needs special attention also with 
regard to medication prescription [26].  
ADHERENCE BEHAVIOUR 
Optimal adherence is characterized by the intake of the correct drug at the prescribed time, 
in the prescribed dosage for the prescribed period of treatment and without unwanted 
combinations. Deviations from this definition can be used to derive the following ten types of 
non-adherence [27]: 
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1) “Parking place effect“: when the patient discards the whole prescribed 
medication, shortly after filling the prescription. This can lead to no or reduced effect 
of the prescribed therapy. 
2) “Drug holiday”: short break of the therapy during persistence (e.g.: due to 
financial reasons). This behavioral pattern can lead to rebound effects and 
development of resistances, as observed in case of antibiotic treatment. 
3) “Toothbrush effect”: the patient begins to follow the otherwise largely ignored 
medical recommendation shortly before the next general practitioners (GP’s) visit. 
This pattern can mask a non-adherence because an effect is seen in short-term 
values but not in the long-term values. 
4) “Wrong medication”: adherent intake of the wrong medication is associated with 
missing or unexpected effects. 
5-7) “Over-, under, and erratic dosage”: dosing errors are associated with reduced 
effect, toxic effects or adverse drug reactions. 
8-9) “Wrong administration frequency and therapy duration”: this is often 
associated with apparent ineffectiveness. 
10) “Polypharmacy“: intake of additional, non-prescribed drugs (OTC-medication), 
which can lead to potential drug interaction. 
TAXONOMY FOR ADHERENCE TO MEDICATION 
In general, various terminologies are used to further specify the different dimensions of 
adherence. Thereby, a taxonomy for adherence to medication has been established.  
The following three terms are utilized to describes the process from the first patient-
healthcare provider contact [28], receiving prescriptions, to taking medication in accordance 
with the individual treatment plan. However, the definitions vary regarding the patient`s 
relationship with the responsible physician [28, 29]. 
• Compliance is the primary term, which was also used in earlier studies analyzing 
“medication-taking” behavior. It describes the degree to which a patient’s behavior 
corresponds with the prescribed therapeutic treatment plan. Within this definition, the 
patient is represented as a passive, obedient recipient of medical advice to which 
he/she should comply [30, 31]. 
 
• The term adherence is used as a synonym for compliance. However, in contrast to 
the “compliant” patient, the “adherent” patient takes an active role, suggesting a 
willing partnership between the patient and the healthcare professional [30, 31]. 
 
• In some cases the term concordance was used to describe the partnership between 
the patient and the healthcare professionals i.e. a trusting relationship with self-
responsible and consensual decisions as well as active involvement of the patient in 
planning and realizing the treatment measures. Thus, the term “concordance” also 
implies that the patients takes over a part of the responsibility for the treatment of 
his/her illness [32]. 
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Two different patterns of non-adherence behaviors are observed in patients, namely 
intentional and unintentional non-adherence: 
• Intentional non-adherence describes the deliberate discontinuation or reduction of 
the intake of medication without feedback to the physician, i.e. in case of absence of 
symptoms [33]. This may be due to a lack of understanding of the course of the 
disease and treatment aims. In addition, the occurrence of side effects can also lead 
to intentional non-adherence [32]. 
• Unintentional non-adherence, however, is observed when patients do not follow 
treatment plans due to reasons out of their control, such as forgetfulness, cognitive 
impairment, or physical disability [32]. In patients taking inhaled medication, impaired 
vision or musculoskeletal disorders can affect their ability to use the inhaler devices 
correctly [34]. Other reasons for unintentional non-adherence are complex medication 
regimes, polypharmacy, and the use of multiple inhalers [35, 36]. 
To distinguish the behavior of medication filling and the actual intake, the terminology of 
primary and secondary non-adherence is used, which is defined as follows [32, 37]: 
• Primary non-adherence represents the lack of filling a first prescription. 
• Secondary non-adherence describes the non-performing of the prescribed 
treatment plan after filling the prescription, including overuse, underuse, forgetfulness 
and deviations from schedules and doses.  
Primary and secondary non-adherence represents a clinically relevant and challenging 
aspect in the treatment of chronic diseases, which physicians and pharmacists encounter 
daily. Furthermore, the gathering of analyzable data is generally difficult. Therefore, Vrjiens 
et al. introduced a conceptional framework, which unifies the variously existing terms in 
adherence trials and can serve as a basis for clinical research. The Ascertaining Barriers to 
Compliance (ABC) taxonomy, considers a sequence of events that have to occur for a 
patient to achieve an optimal benefit from his or her prescribed treatment regimen and to 
minimize the risk of harm [28]. This process is divided into three essential components: 
initiation, implementation, and persistence as  illustrated in Figure 1 [28]. In the ABC 
taxonomy, the process starts with 
• Initiation, which is characterised by the intake of the first dose of a prescribed 
medication. It continues with the 
• Implementation of the dosing regimen defined as the extent to which a patient’s 
actual dosing corresponds to the prescribed medication during the time period from 
initiation to the last dose taken. The last step of this process is 
• Persistence, referring to the time from initiation to eventual discontinuation. After 
discontinuation, a period of non-persistence may follow until the end of the 
prescription period. 
Based on the process steps defined by the ABC taxonomy, non-adherence to medication 
can occur in the following situations: late or non-initiation of a prescribed treatment, 
suboptimal implementation of the dosing regimen or early discontinuation of the treatment. 
This standardized classification is particularly helpful in framing focused research questions 
as well as finding measures and data to answer them. 
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Figure 1. Steps of the adherence process according to the Ascertaining Barriers to Compliance (ABC) team [28]. 
Light blue: process of adherence to medication; dark blue: process of management of adherence. 
The patient’s medication intake behavior can be further described by expressing the 
proportion of the medication taken as prescribed per day (taking adherence) and/or the 
proportion of the medication taken at the right time respectively the right timing intervals 
(timing adherence). These terms are of particular importance since they provide the 
conceptual framework for the approach to measure and quantify medication adherence  [38]. 
MEASUREMENT AND QUANTIFICATION OF ADHERENCE 
In order to investigate the extent and causes of inadequate medication use it is important to 
assess adherence. Methods for the assessment of adherence can be classified into direct 
and indirect methods.  
The only direct approach for the assessment of adherence is the measurement of plasma 
drug concentrations (“Therapeutic Drug Monitoring”). In this approach the ingestion of drugs 
is confirmed by measuring the levels of the drug respectively its metabolite in serum, plasma 
or urine. However, therapeutic drug monitoring is an invasive and expensive method [32], 
and therefore cannot be applied routinely in daily practice. Moreover, it is insensitive to 
inhaled medication. 
Indirect methods include the assessment of a clinical response, pill counts, rates of refilling 
prescriptions, patients self-report and electronic monitoring [38]. Pharmacy refill and 
prescription data are non-invasive, economically efficient and can reflect the real-world 
situation. Data are comparable with electronically measured adherence data. However, with 
pharmacy refill and prescription data it is not possible to observe implementation and 
discontinuation of a therapy plan. At present, none of the above-mentioned methods is 
considered to be the gold standard for the measurement of adherence [39, 40]. Nonetheless, 
electronic monitoring has been increasingly used as a method of choice in clinical trials to 
measure the use of medication [32]. 
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ELECTRONIC MONITORING OF ADHERENCE  
Electronic monitoring  devices were applied in studies from 1980 [41] and firstly reported in 
1984 [42]. Until today, various electronic devices have been developed for the 
measurements of medication adherence, allowing a continual real time monitoring of the 
prescribed treatment. Electronic monitoring devices can deliver data about treatment 
initiation, implementation, discontinuation, and persistence as well as taking and timing 
adherence. With an integrated microprocessor, the time and date are recorded every time 
patients obtain a dose. Thus, electronic monitoring is able to provide precise data on the way 
patients use their prescribed medication.  
Compared to the direct and other indirect methods assessing adherence, electronic 
monitoring has important advantages by:  
• Providing continuous and reliable data on the use of medication with identification of 
days with under-/over-consumption and assessment of dosing intervals [43].  
• Identifying patterns of medication use such as for example “toothbrush” [41, 43].  
• Differentiating between drug resistance and non-adherence in case the prescribed 
medication shows no effect [43]. 
Nonetheless, there are limitations associated with the use of electronic monitoring, e.g. 
erroneously actuation of the device without actually taking the medication. Moreover, 
malfunction of the devices (battery failure, improper initialization or data retrieval problems), 
unreturned devices (disposal or loss of device, forgot to return device) or the use of other 
medication devices by the patients that are not electronically monitored have to be taken into 
account leading to missing data and making their interpretation difficult [43]. Furthermore, the 
actuation of an electronic monitoring device does not necessarily indicate an actual intake of 
the medication. Moreover, monetary aspects may limit the broad application of electronic 
monitoring devices.  
ELECTRONIC MEASUREMENT DEVICES  
Available electronic measurement devices for inhalers vary in function, capability, 
robustness, accuracy and reliability [44]. Currently commercially available devices include 
the Propeller sensor (Propeller Health, Madison, Wisconsin, United States), the Doser 
(Meditrack Products, Easton, Massachusetts, United States) and the SmartInhalerTM 
(Adherium Ltd., Auckland, New Zealand) [44, 45].   
SmartInhalerTM devices are among the most used electronic measurement devices for 
inhalers. These devices consist of additional tools attached to the inhaler devices, which are 
available for metered dose inhaler (SmartTouchTM), Discus® (SmartDiskTM) and Turbohaler® 
(SmartTurboTM) as shown in Figure 2 [46]. The SmartInhalerTM devices have been validated 
for the assessment of adherence to inhaled medication used on a daily basis [47]. They are 
able to track time and date of each actuation of the inhaler device. The incorporated switch is 
activated every time when the MDI is depressed or the DPI is charged (Turbohaler® and 
Discus®). Data obtained with the device are transmitted via a wireless connection to a secure 
Web database and provide numeric and visual data of the records (see Figure 3) [47]. 
SmartInhalerTM devices have been used in several studies measuring adherence to inhaled 
medication [48, 49].  
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In a study of patients with asthma using inhaled corticosteroids, the integrated audio-visual 
reminder function of these devices significantly improved adherence to inhaled medication 
[50]. 
 
Figure 2. SmartInhalersTM: SmartTouchTM for metered dose inhaler (left); SmartDiskTM for Discus® (middle); 
SmartTurboTM for Turbohaler® (right) [51]. 
 
 
Figure 3. Output graph of a SmartInhalerTM adherence recoding. The example shows a typical tracing derived 
from a patient taking preventer medication (4x/d, 2-0-2) and reliever medication over the period of two weeks. On 
April 14th, a day without inhalation is detected. Red bars: preventer medication; blue bars: reliever medication.   
 
Adherence to orally administered drugs or inhaled medications, such as powder capsules, 
can be measured by applying a novel technology called Polymedication Electronic 
Monitoring System (POEMS). This technology consists of printed, self-adhesive polymer film 
carrying loops of conductive wires that can be affixed to multidose punch cards (Pharmis 
GmbH, Beinwil am See, Switzerland) with 28 cavities (see Figure 4). Every time a cavity is 
emptied, an electronic loop is broken inducing changes in electrical resistance that can be 
measured and recorded including date and time [52]. Transmission to an electronic database 
provides numeric and visual data of the records as illustrated in Figure 5. 
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Figure 4. Front side of a multidose punch card (left); back side with a fixed Polymedication Electronic Monitoring 
System (POEMS, right). 
 
 
Figure 5. Output graph of a Polymedication Electronic Monitoring System (POEMS) adherence recording of a 
patient taking a once-daily medication regimen over the period of two weeks.  
STRATEGIES TO IMPROVE ADHERENCE  
Maintenance of sufficient adherence to the prescribed medication is a critical factor in 
achieving therapeutic success, particularly in chronic diseases. In a review of randomized 
controlled intervention trials to improve adherence to pharmacological regimens in patients 
with chronic diseases, including asthma, Haynes et al. found that less than 50% of the 
interventions achieved a significant improvement of adherence and only 30% demonstrated 
an improvement in clinical outcomes [53]. The greatest success was attained with complex 
interventions combining several strategies (information, reminders, self-monitoring, 
reinforcement, counseling, telephone follow-up, supportive care). [53]. Lu et al. [54] 
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demonstrated that disease management interventions were associated with short and long-
term improvements with regard to the process and quality of care in particular, when using 
structured, population-based and multidisciplinary approaches for the identification, treatment 
and monitoring of patients with chronic illness. This review also suggested that coordinating 
pharmacist services as a component of the process of care can improve quality of life, 
medication adherence, and clinical outcomes in chronically ill patients [54]. 
Electronic medication packaging, including adherence records, audiovisual reminder, digital 
displays and real-time monitoring as characteristics, showed an effect on mean adherence 
which ranged from a decrease of 2.9% to an increase of 34.0% [55]. Complex interventions 
that applied both, electronic devices and e.g. alarms [55] or feedback on the patient’s 
adherence performance [56] showed the greatest success.  
However, particularly successful intervention components could not be determined 
specifically [57]. The evidence supporting adherence-improvement intervention remains poor 
and the effect on adherence, clinical outcomes, and economic-efficiency is moderate. 
EXTENT AND CONSEQUENCES OF NON-ADHERENCE  
In general, adherence can vary from 0% to more than 100% the latter in case patients 
take/inhale more than the prescribed doses. Overall, rates around 80% are considered to be 
acceptable [58] depending on the indication. For chronic diseases, adherence has been 
described to vary between 43% and 78% [59, 60]. As discussed earlier, non-adherence can 
already begin when filling a prescription. A prospective cohort study conducted in Canada 
analyzing 15’961 patients, revealed that primary non-adherence was as low as 31.3% [61]. 
Furthermore, this study demonstrated that patients with a new prescription had a lower filling 
rate of 34.3% compared to patients who switched treatment (11.6%) [61].  
After having started the prescribed therapy, further conditions may potentially affect 
adherence. Thus, higher adherence rates have been described in patients taking their 
medication in the morning compared to those taking it in the evening [62]. Furthermore, 
taking and timing adherence was generally higher for once-daily regimens than for two-, 
three- and four- times daily regimens [63]. 
Various studies have consistently demonstrated that non-adherence is associated with 
reduced effectiveness and safety of treatments, which in turn can lead to adverse health 
outcomes and may range from drug resistance to transplant rejection [64-66]. In general, 
non-adherence may lead to adverse drug effects, disease progression due to treatment 
failure and finally to increased hospitalization rates and mortality [67-69]. 
While regular medication intake can lead to an improvement in health-related quality of life 
[70-72], the high medication burden and the lack of flexibility in many medication regimens 
applied in daily life may have a negative impact on the quality of life of these patients [73]. 
This can result in patients deciding to be non-adherent. Overall, patients non-adherence to 
prescribed medication may be associated with poor therapeutic outcomes, progression of 
diseases, and a massive financial burden in form of increasing direct costs for the healthcare 
systems [74]. 
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RATIONAL AND APPROACH 
Despite important progresses achieved in pharmacological and non-pharmacological 
treatment, disease control remains to be suboptimal. The majority of the affected patients 
suffers from severe symptoms and tends to be frequently hospitalized due to exacerbations. 
These patients report a reduced health status, which also impacts their families as well as 
the society as a whole. 
Approximately 50-75% of the costs of healthcare services for COPD patients are caused by 
exacerbations [75]. This is due to the fact that exacerbations mostly lead to hospital stays, 
physician visits, additional medication and can also have serious consequences regarding 
quality of life, lung function and mortality [76]. Acute exacerbations are a risk factor for 
disease deterioration and it has been shown that frequent exacerbations are associated with 
a high mortality [67, 68]. On the other hand, it has been demonstrated that the administration 
of certain medication can significantly reduce the exacerbation frequency [77, 78]. There is 
also evidence that high adherence is associated with reduced exacerbation rates in patients 
with asthma [79-81] and COPD [82]. 
As outlined above, maintaining adequate adherence to inhaled medication is of major 
importance for achieving therapeutic success, in particular for treatment of chronic diseases. 
Different interventions and strategies are already described in the literature aiming to 
enhance adherence. The greatest success was attained with complex interventions 
combining several strategies [53]. However, to date no intervention was determined to be 
particularly successful [57]. 
Therefore, this thesis aims to contribute to this challenging but important research field by 
investigating the impact of two simple interventions on adherence to inhaled therapy in 
patients with asthma and COPD.  
Prior to the study start, we provided a training course for each participant regardless of the 
treatment group to guarantee a comparable level of disease knowledge and inhalation 
technique. Further, each patient was equipped with an electronic monitoring device, which 
was used as the method of choice for the assessment of objective adherence. Overall, the 
performed intervention consisted of a reminder in form of phone calls and a daily alarm clock 
as well as feedback on patients’ individual adherence profile. The combination of these two 
common types of interventions has been chosen since they appeared to be easily applicable 
in daily clinical practice. We considered this to be one of the important factors in order to 
guarantee an efficient improvement of patients’ adherence.  
By the intervention, we expected a prolongation of time to next exacerbation, which was 
defined as the primary endpoint of this study. Moreover, we assumed an improvement of 
patients’ taking and timing adherence as well as quality of life, determined as the two 
secondary endpoints. 
The thesis is divided into the following three parts: 
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PART I: STUDY PROTOCOL  
Impact of an Electronic Monitoring Intervention to Improve Adherence of Inhaled 
Medication in Patients with Asthma and Chronic Obstructive Pulmonary Disease: 
Study Protocol for a Randomized Controlled Trial 
The aim of this first part was to design and write a study protocol taking into account the 
above-mentioned aims and under consideration of the current state of the literature as well 
as the studies already conducted in this field. 
PART II: BASELINE DATA 
Prescription and Use of Inhaled Medication in Patients with Asthma and COPD: 
Baseline Data of an Adherence-Intervention-Study  
The aim of this cross-sectional analysis was to evaluate baseline data on compliance in 
accordance with current treatment guidelines (Global Initiative for Asthma (GINA) and Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines). Furthermore, it intended 
to provide baseline data on inhaler application after a training course and its impact on 
quality of life and symptom control in a typical population with chronic lung diseases from the 
Adherence-Trial. 
PART III: OBJECTIVE ADHERENCE AND HEALTH-RELATED  OUTCOMES  
Impact of an electronic monitoring intervention on exacerbations in chronic lung 
patients  
The aim of this last part was to analyze the time to next exacerbation - the primary endpoint 
of the study – which was evaluated and compared between the intervention and the control 
group. Furthermore, the objective adherence was analyzed by evaluating the taking and 
timing adherence, as well as the gaps during the study period. Patients’ quality of life was 
assessed by the St. George Respiratory Questionnaire (SGRQ). 
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ABSTRACT 
Background: Despite progress in pharmacological and non-pharmacological treatment in 
recent years, the burden of disease among patients with asthma and chronic obstructive 
pulmonary disease (COPD) is high and patients are frequently hospitalized due to 
exacerbations. Reasons for uncontrolled diseases are manifold, but are often associated with 
poor inhalation technique and non-adherence to the prescribed treatment plan. This causes 
substantial mortality, morbidity, and costs to the healthcare system. In this respect, the study 
of causes for non-adherence and the development of measures to increase and maintain 
treatment adherence in chronic diseases is of major clinical importance. 
Objective: The primary objective of this study is to investigate the impact of using specific, 
validated electronic devices on adherence to inhaled medication in patients with chronic 
obstructive lung diseases such as asthma and COPD. Furthermore, it aims at assessing the 
impact of a reminder and a close supervision of the course of diseases and quality of life.  
Methods: In this ongoing prospective, single-blind randomized controlled study, adherence 
to inhaled medication is analyzed over a 6-month period in at least 154 in- and outpatients 
with asthma or COPD who have experienced at least 1 exacerbation during the last year. 
Adherence is measured using electronic data capture devices, which save date and time of 
each inhalative device actuation and transfer these data daily via a wireless connection to a 
Web-based database. Patients are randomly assigned to either the intervention or the control 
group. The clinical intervention consists of an automated and personal reminder. The 
intervention group will receive an audio reminder and support calls in case medication has 
not been taken as prescribed or if rescue medication is used more frequently than pre-
specified in the study protocol. During the study, participants are assessed every 2 months in 
the form of clinical visits. 
Results: Recruitment started in January 2014. To date, a total of 169 patients have been 
recruited. Follow-up assessments are still ongoing. The study will be concluded in the first 
quarter of 2017. Data analysis will take place during 2017.  
Discussion: Few studies have investigated medication adherence in patients with chronic 
obstructive lung diseases. With this prospective study design and the use of state-of-the-art 
devices for measuring adherence, we expect scientifically relevant and clinically meaningful 
results that will have a substantial and positive impact on the provision of healthcare in 
chronically ill patients suffering from asthma or COPD.  
Trial registration: ClinicalTrials.gov: NCT02386722;  
 
 
Keywords: asthma; pulmonary disease, chronic obstructive; medication adherence; 
randomized controlled trial 
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INTRODUCTION  
Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent lung 
diseases requiring daily and often lifelong use of inhaled medication [1]. According to the 
World Health Organization (WHO), COPD currently represents the fourth leading cause of 
death worldwide and is predicted to become the third leading cause of death by 2030 [2]. 
The prevalence of COPD is increasing due to continuing exposure to COPD risk factors 
(e.g., tobacco smoke or air pollution) and the continuously aging world population [3]. The 
prevalence of asthma is increasing as well [4]. In Swiss adults, the prevalence of asthma and 
COPD was found to be around 7% and 7% to 9%, respectively [5,6].  
TREATMENT AND DISEASES CONTROL 
Despite progress in pharmacological and non-pharmacological treatment in recent years, the 
burden of disease imposed by asthma and COPD remains high and patients may be 
frequently hospitalized due to exacerbation. Based on data from the Swiss COPD Cohort 
Study, COPD exacerbation rates are high, at 23% per year [7]. Acute exacerbations are a 
risk factor for disease progression and are associated with increased mortality [8]. A survey 
published by Leuppi et al showed that the level of asthma control in Switzerland is very low 
with 15% of the investigated patients [9]. This has also been confirmed by a cross-sectional 
survey by Miedinger et al who found controlled asthma in 27% of all patients according to the 
international Global Initiative for Asthma (GINA) guidelines [10]. However, good adherence to 
therapy can increase the likelihood of achieving better disease control [11].  
Reasons for insufficient disease control in asthma and COPD patients are manifold. They are 
frequently associated with poor inhalation technique and non-adherence to prescribed 
treatment plans, which may influence mortality and morbidity and pose a financial burden on 
healthcare systems [12]. 
MEDICATION ADHERENCE 
According to the WHO, adherence is defined as "the extent to which a person’s behavior 
(including medication-taking) corresponds with agreed recommendations from a health care 
provider" [13]. Adherence represents the basis for effective drug therapy and complete 
disease control. It is a multidimensional issue with several influencing factors. The WHO 
classifies these factors into 5 dimensions: socioeconomic-related factors, healthcare team 
and system-related factors, condition-related factors, therapy-related factors, and patient-
related factors [13]. Furthermore, 2 different patterns of non-adherence behaviors are 
observed in patients, namely intentional and unintentional non-adherence. Intentional non-
adherence describes the deliberate discontinuation or reduction of the intake of medication in 
case of absence of symptoms [14], which may be due to a lack of understanding of the 
disease course and treatment aims. In addition, the occurrence of side effects can also lead 
to intentional non-adherence. Unintentional non-adherence, however, is observed when 
patients do not follow treatment plans due to reasons out of their control, such as 
forgetfulness, cognitive impairment, or physical disability [15]. In patients taking inhaled 
medication, impaired vision or musculoskeletal disorders can affect their ability to use the 
inhaler devices correctly [16]. Other reasons for unintentional non-adherence are complex 
medication regimes, poly-pharmacy, and the use of multiple inhalers [17,18]. Non-adherence 
not only leads to suboptimal treatment of individual patients, but may also cause disease 
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prolongation and increased hospital readmission. Finally, it can increase costs for the 
healthcare system [19].  
Based on a systematic literature review of medication adherence literature, Vrijens et al 
proposed a new taxonomy for describing and defining adherence to medication [20]. The 
Ascertaining Barriers to Compliance (ABC) taxonomy considers a sequence of events that 
have to occur for a patient to achieve an optimal benefit from their prescribed treatment 
regimen and to minimize the risk of harm. This process is divided into 3 essential 
components: initiation, implementation, and persistence. The process starts with the initiation 
characterized by the intake of the first dose of a prescribed medication. It continues with the 
implementation of the dosing regimen, which is defined as the extent to which a patient’s 
actual dosing corresponds to the prescribed medication during the time period from initiation 
to the last dose taken. The last step of the process is persistence, which refers to the time 
from initiation to eventual discontinuation. After discontinuation, a period of non-persistence 
may follow until the end of the prescription period.  
As such, non-adherence to medications can occur in the following situations: late or non-
initiation of a prescribed treatment, suboptimal implementation of the dosing regimen, or 
early discontinuation of the treatment. This classification is particularly helpful in framing 
focused research questions as well as finding measures and data to answer them.  
Adherence to long-term therapy is estimated to be around 50%, as shown in a systematic 
review summarizing the results of randomized controlled trials (RCTs). It investigated 
interventions in order to help patients follow prescriptions for medications [21]. Among 
patients with asthma, rates of non-adherence ranged from 30% to 70% [22]. Levels of non-
adherence are comparably high in patients with COPD, ranging from 43% to 58% [23,24]. 
Adherence to medication can be measured using direct or indirect methods. Direct methods 
encompass direct observation of drug intake or measurement of drug concentration, such as 
markers in the blood, urine, or other body fluids. Indirect methods include assessment of a 
patient’s clinical response, pills count, rates of refilling prescriptions, patient’s self-report, or 
the use of electronic monitoring devices [25,26]. While none of these methods are currently 
considered the gold standard for measuring adherence to medications [27,28], the emerging 
method of choice are electronic monitoring devices [29].  
Self-reporting by patients was shown to be the most cost-effective approach to the 
assessment of adherence in clinical and research settings [30]. However, being a subjective 
method, it also bears the highest risk of overestimating adherence compared to electronic 
measurements [31].  
Observational retrospective studies based on dispensing data from pharmacy record 
databases analyzed refill adherence for different inhaled medication in patients with asthma 
and COPD [32-34]. The importance of refill adherence is limited, since this measurement 
cannot assess the timing of the ingested or inhaled doses that depend on the duration of 
drug action, which in turn has an important impact on the efficacy of treatment [35].  
To investigate the variability in timing and medication adherence, measurements of dose and 
timing are necessary, which can be done with electronic medication monitors. Electronic 
monitoring provides precise data on timing and the pattern of inhaler actuation. In addition, it 
may detect multiple successive actuations (dumping) [36].  
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Electronic monitoring methods such as SmartInhaler devices (Adherium Ltd., Auckland, New 
Zealand) are non-invasive and represent one of the best ways to detect adherence patterns 
when using additional tools attached on the inhaler devices [37]. The SmartInhaler devices 
have been validated for the assessment of adherence to inhaled medication on a daily basis 
[38]. They are able to track time and date of each actuation of the inhaler device 
(incorporated switch activates by depression or rotation of the device) and transmit the data 
via a wireless connection to a secure Web database [38]. SmartInhaler devices have been 
used in several studies measuring adherence to inhaled medication [39,40]. In a study on 
patients with asthma using inhaled corticosteroids, the integrated audio-visual reminder 
function of these devices significantly improved adherence to inhaled medication [41]. 
Adherence to orally administered drugs or inhaled medications available, such as powder 
capsules, can be measured by applying a novel technology called Polymedication Electronic 
Monitoring System (POEMS). This technology is composed of printed, self-adhesive polymer 
film carrying loops of conductive wires that can be affixed to multidose punch cards (Pharmis 
GmbH, Beinwil am See, Switzerland) with 28 cavities. Every time a powder capsule is taken 
out of the blister, a loop is broken leading to changes in electrical resistance that can be 
measured and recorded with date and time [42]. The reports generated by Smartinhalers and 
POEMS detect whether the patients have taken the medication at the right time and dose. 
INTERVENTIONS TO IMPROVE MEDICATION ADHERENCE 
Maintenance of sufficient adherence to the prescribed medication is a critical factor in 
achieving therapeutic success, particularly in chronic diseases. Haynes et al [43] reviewed 
randomized controlled intervention trials to improve the adherence to pharmacological 
regimens in patients with chronic diseases, including asthma. Both adherence and clinical 
outcomes were measured in these studies. The authors found that less than 50% of the 
interventions achieved a significant improvement of adherence while only 30% demonstrated 
an improvement in clinical outcome. The greatest success was attained with complex 
interventions combining several strategies (information, reminders, self-monitoring, 
reinforcement, counseling, telephone follow-up, supportive care, etc). [43]. Lu et al [44] 
showed that disease management interventions are associated with short and long term 
improvements with regards to the process and quality of care. In particular, when using 
structured, population-based and multidisciplinary approaches for the identification, 
treatment, and monitoring of patients with chronic illness. This review also suggested that 
coordinating pharmacist services as a component of the process of care can improve quality 
of life, medication adherence, and clinical outcomes in chronic patients [44]. However, 
particularly successful intervention components could not be determined specifically [45]. 
STUDY OBJECTIVE 
The objectives of this study are (1) to investigate the impact of using specific, validated 
electronic devices on adherence to inhaled medication in patients with asthma and COPD; 
and (2) to assess the effect of an acoustic reminder and a close supervision on the course of 
diseases and quality of life. 
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METHODS 
PARTICIPANTS AND RECRUITMENT 
In- and outpatients with a diagnosis of asthma bronchiale or COPD from several hospitals in 
the Basel region and patients treated by pulmonologists in private practice are screened for 
eligibility (Table 1). Advertisements are distributed in the form of posters, flyers, as well as on 
ad-screens (Cantonal Hospital Baselland Liestal and Bruderholz), communicating the most 
important information about the study. Advertisements are also placed in local newspapers.  
Table 1.Recruitment locations and related recruitment types. 
Hospital Location  Type of Recruitment 
Cantonal Hospital Baselland  Liestal, 
Switzerland 
Screening of hospitalized patients 
 
  Screening of emergency department 
 
  Screening of DRGa-lists 
Cantonal Hospital Baselland Bruderholz, 
Switzerland 
Screening of DRGa-lists 
 
  Collaboration with pulmonology 
department 
Claraspital  Basel, 
Switzerland 
Collaboration with pulmonology 
department 
Clinic Barmelweid   Barmelweid, 
Switzerland  
Collaboration with pulmonology 
department 
Gesundheitszentrum Fricktal 
AG 
 
Rheinfelden, 
Switzerland 
Collaboration with pulmonology 
department 
aDRG: diagnosis related groups. 
  
Initially, inclusion and exclusion criteria are checked via telephone, during hospitalizations, or 
practice visits. Eligible patients are invited for an introductory training course. Before the start 
of the study, the investigator provides written and verbal information about content and 
duration of the study. The investigator will obtain written consent from patients confirming 
their willingness to participate in the study. 
INCLUSION AND EXCLUSION CRITERIA 
The study inclusion and exclusion criteria for male and female participants are shown in 
Textbox 1 [46]. Enrolment started January 2014 and will end when at least 154 individuals 
are included in the study.  
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Textbox 1. Inclusion and exclusion criteria. 
Criteria 
• Inclusion 
o Aged 18 years or older 
o Have an established asthma-diagnosis according to the Global Initiative for 
Asthma (GINA) guidelines and/or  
o Have an established COPD diagnosis according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guidelines (severity GOLD I-IV 
based on the international GOLD-Criteria) [46] and 
o Are prescribed daily inhaled medication (controller medication for a daily 
maintenance treatment) 
o Had at least one exacerbation in the previous 12 months before study start 
• Exclusion 
o Suffering from malignancies and/or other severe diseases  
o Insufficient in the German language  
o Pregnant or lactating  
STUDY DESIGN AND PROCEDURES 
In this prospective, single-blinded RCT, 169 participants are followed for up to 6 months 
(Figure 1). Prior to study start, patients have to be in a stable phase of their obstructive lung 
disease. This is defined as an exacerbation-free period of at least 1 month prior to 
commencement of the study and no current hospitalization for any other medical condition. 
Study participants will continue to be cared by their usual treating physician(s). They decide 
on all prescriptions and treatments.  
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Figure 1. Study flow chart based on the CONSORT (consolidated Standards of Reporting Trials) guidelines. 
All participants take part in a training course before the baseline visit, which takes 
approximately 45 to 60 minutes. The goal of the training course is to provide refresher 
training on inhalation techniques in order to ensure that all participants are at the same level 
of disease knowledge and use their medication correctly. The training begins with a brief 
introduction about asthma and COPD. Afterwards, the most frequently used devices are 
presented and briefly demonstrated. Correct technique depends on inhaler type and it is 
important that patients use their own inhaler correctly. Common mistakes and problems 
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associated with the use of the devices are explained. The correct use of the individual 
devices is demonstrated in a short film (produced by the "Deutsche Atemwegsliga" Bad 
Lippspringe, Germany) [47], which presents the most important steps to follow in order to 
achieve an effective inhalation. Notably, it has been shown that the manufacturer’s 
instruction sheet is not effective enough to achieve correct techniques [48-50]. However, the 
combination of verbal and visual instructions seems to have a higher success rate in 
improving the application of inhaler devices [51]. At the end of the training, participants are 
given the opportunity to ask questions concerning the devices.  
Visits take place at baseline (T0), after 2 (T1), 4 (T2), and 6 months (T3) and will take 
between 45 to 60 minutes, depending on the patient, regardless of the group they belong to. 
Each visit includes a spirometry (EasyOne Pro, ndd Medizintechnik AG, Zurich, Switzerland), 
measurement of diffusion capacity (EasyOne Pro, ndd Medizintechnik AG, Zurich, 
Switzerland), exhaled nitric oxide (NIOX MINO, Aerocrine AB, Sweden) and carbon 
monoxide (piCO+ Smokerlyzer, Bedfont Scientific Ltd., Kent, UK). To detect false device 
applications, each patient is asked to demonstrate the inhalation technique with all 
prescribed devices to the investigator by using a placebo device (to avoid overdosing). 
Moreover, participants have to complete the COPD Assessment Test (CAT) [52], the Asthma 
Control Test (ACT) [53], the St. George’s Respiratory Questionnaire (SGRQ), and the Short 
Form (SF)-36 [54,55] to assess quality of life at baseline, after 2, 4, and 6 months. To 
investigate patients’ beliefs about the necessity of the prescribed medication as well as their 
concerns about the potential adverse consequences of taking it, the Beliefs about Medicines 
Questionnaire (BMQ) is used at baseline [56,57]. Throughout the 4 visits, further obtain 
information about exacerbation since the previous visit is obtained. 
RANDOMIZATION 
Participants are randomly assigned either to the intervention or to the control group. The 
intervention group is provided with an acoustic reminder for inhalation and receives support 
calls when the medication is not taken as prescribed, whereas the control group receives no 
further support regarding their adherence. A randomization list with study group allocation is 
generated by using R (RStudio, Boston, US). The randomization procedure is provided in 
block size of 2. Therefore, examinations between study groups are sequent. This reduces 
the risk of a season effect between the 2 study groups. Furthermore, the patients are not 
aware of which group they have been randomized to (single-blinded). 
CLINICAL INTERVENTIONS 
The clinical intervention consists of an automated and personal reminder. Patients assigned 
to the intervention group receive an audio-reminder, generated by a mobile phone with app 
capabilities (smartphone). For patients with Smartinhaler, the inhalation times are entered on 
the Smartinhalerlive website by the investigator. These are then generated by an app directly 
onto the participant’s mobile phone. For patients using POEMS, the inhalation times are 
entered by the investigator directly in form of an alarm clock onto the mobile phone. Patients 
are allowed to choose the inhalation times themselves, depending on their personal habits 
and daily routine. Additionally, it is possible to define a time for the working days and a time 
for the weekend. Since the inhalation actuation does not stop the device alarms, the 
reminder generated by the Smartinhaler app and those generated by the mobile phone, have 
to be quitted by the patients themselves. Moreover, these patients receive support calls 
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carried out by the pharmacist when the use of rescue medication doubles or if the inhaled 
medication is not inhaled as prescribed for more than 2 consecutive days. In exceptional 
cases and in the absence of the pharmacist, the support calls are carried out by the 
responsible study nurse who has been trained accordingly. Participants also receive a 
feedback from the pharmacist on their adherence at each visit, especially for the results of 
the POEMS. 
Patients assigned to the control group have no reminder and will receive no further support 
regarding their adherence to their inhaled medication. 
SAMPLE SIZE 
Power calculation is based on "time to next exacerbation." A previous study has shown that 
30% of patients with COPD are readmitted within 6 months because of an exacerbation [58]. 
Exacerbation rate could be reduced by 30% with an educational program [59]. Since our 
intervention is not only based on an educational program but on a close supervision during 
the study period, we expect a bigger effect of our intervention, resulting in an assumed 
endpoint reduction of 60% (12/30), with 12% (8/70) of patients experiencing an exacerbation 
in the intervention group. This corresponds to a hazard ratio (HR; intervention/control) of 
0.36, taking into consideration the time-to-event-curve for the primary outcome (time to next 
exacerbation). Assuming a sample size of 70 participants for each study group, there is a 
power of 80% to detect a HR of 0.36 based on a 1-tailed test, since only a decrease of the 
exacerbation-risk is of interest and expected. The calculation is based on the assumptions 
mentioned above and on a 1-tailed test with a significance level of 5%. Furthermore, 14 
additional participants (7 for each study group) were added to account for dropouts. 
Therefore, a total of 154 participants will be included in this study. 
MEASUREMENT OF OBJECTIVE ADHERENCE 
In both groups, adherence is measured using Smartinhalers and POEMS as outlined above. 
Daily measurements are started after the baseline visit (T0) and are continued until the end 
of the study (T3). All participants are aware that their adherence is measured during the 
whole study period using the delivered devices. Hence, a possible "hawthorne effect" can 
result, which represents a change in patient’s behavior as a consequence of being monitored 
during a study [60]. However, previous studies showed that there is no better adherence in 
patients who were informed that their drug intake was being monitored compared to those 
patients who were unaware of the monitoring [61,62].  
Recorded data are uploaded daily at 00:00 to a Web-based database via a wireless 
connection. Participants are asked to take their medication at the first visit in order to ensure 
the correct handling and usage of the Smartinhaler. Once the devices are installed on the 
inhalers, patients can use their medication as usual. 
Currently, no monitoring devices exist that are specifically developed for monitoring the 
adherence of the newly introduced inhalation-device Ellipta. To assess adherence in patients 
undergoing treatment with Ellipta, a Smartinhaler with a placebo-device is handed out and 
patients are instructed to trigger a puff of the placebo every time when they inhale their active 
treatment. This procedure allows an indirect recording of date and time actuation of the 
Ellipta inhaler.  
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POEMS are used for inhalation with powder capsules (Breezhaler and HandiHaler). The 
capsules are pre-filled for the following 2 weeks with a patient’s individualized prescription 
plan (mostly one time daily inhalation of capsule contents). The multidose punch cards are 
filled manually by a pharmacist. Participants who apply Breezhaler and HandiHaler will 
receive 1 multidose punch card for every 2 weeks. Every time the patients break a loop for 
taking the capsules, date and time are recorded on a microchip, which can be read out when 
patients bring back the empty punch card.  
DATA COLLECTION AND OUTCOME MEASURES 
The primary outcome of this study is "time to next asthma or COPD exacerbation," defined 
as acute-onset worsening of the patient’s condition beyond day-to-day variations requiring 
interaction with a health care provider [63]. Outcome is expressed as the number of 
exacerbations since the last visit with the exact period of exacerbation as well as the number 
of exacerbation followed by hospitalization. If patients are not able to provide information 
about the time of exacerbation, the treating physician will be contacted.  
Sociodemographic variables such as gender, civil status, age, educational level, and 
employment status are obtained by a generic questionnaire during the baseline visit. 
Furthermore, smoking status is assessed from medical history and expressed as pack years 
(py) (number of smoking years times number of smoked packs per day). Body height and 
weight are signified by the body mass index (BMI; body weight/[body height]2). In addition, 
disease-related questions such as allergies, comorbidities, current medication, and number 
of exacerbations in the previous 12 months are recorded, including hospitalizations and 
emergency department attendance.  
This project focuses on the implementation of a prescribed dosing regimen. Objective 
adherence will be analyzed according to the definitions shown in Textbox 2 [64].  
 
Textbox 2. Objective adherence definitions. 
Definition 
• Taking adherence: (number of puffs inhaled during 24 hours/number of puffs 
prescribed during 24 hours) x 100 
• Timing adherence: (number of correct dosing intervals during 24 hours/number of 
dosing intervals during 24 hours) x 100; correct dosing intervals are prescribed 
intervals ± 25%: 
o For once daily dosing: 24 hours ± 25% = 18 hours to 30 hours 
o For twice daily dosing: 12 hours ± 25% = 9 hours to 15 hours 
o For three daily dosing: 8 hours ± 25 % = 6 hours to 10 hours 
• Gaps: (number of days without inhalation during the whole study period/number of 
days in same time period) x 100 
• Maximal gap length: number of consecutive days of the longest period of time without 
inhalation 
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Throughout all visits, the following lung function tests are performed to assess changes in 
lung function: spirometry (FEV1, FVC, FEV1/ FVC), diffusion capacity, NO- and CO-
measurements. 
During each visit (T0 to T3), participants are asked to demonstrate how they actually use 
their device at home to evaluate the inhalation technique. For this purpose, placebo devices 
are used to prevent overdosing. Correctness of inhaler use is assessed using pre-defined 
checklists for each inhaler type based on user guidelines and instruction package inserts 
from the manufacturers [65-70]. Correct inhaler usage is defined as correct performance of 
every step on the checklist. Incorrect inhaler usage is defined as 1 or more steps done 
incorrectly. A total score is calculated with 0 (incorrect application) and 1 (correct application) 
and applied to every step. Possible errors are corrected by verbal instruction and visual 
demonstration. For ethical reasons the correction was performed in both groups. Patients 
demonstrate their inhalation technique until it is performed correctly.   
At baseline, the BMQ is used to assess patients’ beliefs about the need of the prescribed 
medication and their concerns about the potential adverse consequences of taking it.  
Changes in quality of life are investigated at baseline, after 2, 4, and 6 months using different 
disease-specific questionnaires: SGRQ, CAT, and ACT. To determine general quality of life, 
the SF-36-questionnaire is used.  
Data collection will end as soon as all study participants have finished the 6-month 
observational period and have had the fourth clinical visit. 
STATISTICAL ANALYSIS 
Statistical analyses, including descriptive statistic and survival analyses, are carried out by 
using the software R (RStudio, Boston, US) and SPSS (IBM Corporation, Armonk, US). 
Statistical significance is set at the 5% level. Time to next exacerbation is compared by 
applying the Kaplan-Meier method and Cox proportional hazard model. Results will be 
reported as a HR with a corresponding confidence interval (CI) of 95 % and P value. A HR 
smaller than 1 is expected. This implies that the intervention group will have a smaller risk for 
exacerbations. Associations between time to between exacerbation and independent 
predictors will be analyzed (taking adherence, timing adherence, and gaps without 
inhalation). Comparisons of secondary parameters are done using t tests or chi-square tests 
(or their nonparametric equivalents if data are not normally distributed). 
MISSING DATA AND DROPOUTS 
Patients will be rated as dropout when they are excluded from the study at their own request 
or if they are no longer able to participate in the study until the final visit. Patients who are not 
able to undergo all clinical examination during the follow-up visits will remain in the study. 
Multiple imputation methods will be used to impute missing data with less than 25% missing 
values. This is typically more efficient than complete case analysis when covariates have 
missing values [71]. 
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ETHICS AND DISSEMINATION 
This study is conducted according to the Helsinki Declaration and according to the good 
clinical practice guidelines. Study participation is voluntary and can be revoked at any time 
without specification of reasons and will have no disadvantages for their future medical care. 
The study was approved by the Ethics Committee Northwest/Central Switzerland (registry 
number: EK-269/13) and was registered with Clincialtrials.gov (NCT02386722). In case of 
any considerable deviations from the actual study protocol, the investigator will send an 
amendment for further approval from the ethical committees. The results of this study will be 
disseminated via seminar, conference presentations, and academic, peer-reviewed journals. 
DATA SECURITY AND DISCLOSURE OF ORIGINAL DOCUMENTS 
Patient data are collected and stored under confidentiality rules. For reports, data collection, 
and administrative forms an anonymization will be done and participants will be assigned a 
study identification (ID) (PXXX). All study-related data and documents are stored on a 
protected server of the Cantonal Hospital Baselland. Data access is limited to members of 
the medical research group at the Cantonal Hospital Liestal. After study completion, all 
documents and informed consent formed will be retained in the archives of the University 
Department of Internal Medicine at the Cantonal Hospital Liestal for 10 years according to 
applicable Swiss regulatory requirements. 
RESULTS 
This is a single-centre, randomized controlled study. It is performed at the Cantonal Hospital 
Baselland, Liestal, and Bruderholz, Switzerland. Recruitment started in January 2014, and to 
date, a total of 169 patients have been recruited. Follow-up assessments are still ongoing. 
The study will be concluded in the first quarter of 2017. Data analysis will take place during 
2017.  
DISCUSSION 
To date, only a few studies have investigated medication adherence in patients with chronic 
obstructive lung diseases. These studies were retrospectively analyzed, limited to refill 
adherence, and comprised several important limitations, including the lack of assessment of 
the relationship between the duration of drug action and the timing of the ingested doses, 
which impacts the efficacy of treatment [15]. Other disadvantages of this measurement are 
missing data in case of refills obtained outside of the investigated system and incomplete 
records if the medication plan is verbally modified by the prescriber without informing the 
dispensing pharmacy. Moreover, assumptions have to be made on medication intake 
behavior, if it is taken accordingly to the prescription, and corresponds to the prescribed 
refilling [72]. 
We expect that a regular adherence reminder and close supervision by a healthcare 
professional will have a beneficial effect on adherence to inhaled medication in patients with 
asthma or COPD, resulting in an increased time to next exacerbation. In addition, we 
assume that improved adherence will increase the quality of life of these patients. 
With the prospective study design and the use of state-of-the-art devices for measuring 
adherence, we expect scientifically relevant and clinically meaningful results that will have a 
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substantial and positive impact on the provision of healthcare in chronically ill patients 
suffering from asthma or COPD.  
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ABSTRACT  
Background: In Swiss adults, prevalence of asthma and COPD is around 7%. To date, 
asthma and COPD are not curable but treatable respiratory diseases. The burden of each 
disease among patients is high and people affected are frequently hospitalized due to 
exacerbations. This is associated with accelerated lung function decline, increased mortality 
and reduced health-related quality of life (HRQoL). However, there are numerous reasons for 
the lack of disease control in asthma and COPD patients. It is repeatedly associated with 
non-adherence to guidelines regarding treatment recommendation on the part of the 
healthcare provider and with poor inhalation technique and/or non-adherence to the 
prescribed treatment plan by the patient. 
Objective: This study aims at presenting data on compliance in accordance with current 
treatment guidelines. Moreover, we provide baseline data on inhaler application and its 
impact on quality of life and symptom control in a typical population with chronic lung disease 
from the Adherence-Trial. 
Methods: For this cross-sectional analysis, 169 in- and out-patients with asthma and COPD 
were recruited. Correct application of inhaler devices was tested using pre-defined 
checklists. Quality of life and symptom control were investigated using COPD Assessment 
Test (CAT) and Asthma Control Test (ACT). Spirometry was used to measure forced vital 
capacity (FVC) and forced expiratory volume in one second (FEV1). 
Results: Overall, correct inhalation technique ranged from 55% to 100% depending on the 
type of inhaler. 112 participants (68%) participants were treated according to global 
guidelines. COPD patients with incorrect device application had a higher CAT sum score 
compared to those with a correct device application (p=.02). Moreover, COPD patients with 
incorrect device application had more often cough (p=.03) and were more breathless while 
walking up hills or one flight of stairs (p=.02). While there was no significance found in 
asthma patients, COPD patients who used their devices correctly had a significantly better 
mean FEV1% predicted at baseline compared to those who applied their devices incorrectly 
(p=.04).  
Discussion: Regular and comprehensive training of correct an inhalation technique is 
recommended in patients with chronic lung disease, in particular COPD. Correct inhalation of 
prescribed medication is associated with improved health status and lung function. These 
findings should encourage physicians and pharmacists to provide instructions on correct 
inhalation technique and to re-evaluate the patients’ inhalation technique on a regular basis. 
Trial registration: ClinicalTrials.gov: NCT02386722 
 
 
Keywords: asthma; pulmonary disease, chronic obstructive; inhalation technique; dry 
powder inhalers; metered dose inhalers; quality of life 
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INTRODUCTION 
Asthma bronchiale and Chronic Obstructive Pulmonary Disease (COPD) are chronic 
respiratory diseases that are highly prevalent in the overall population [1]. Asthma is 
estimated to affect between 1 and 18% of the population, while approximately 6% of the 
adult population have been diagnosed with COPD [2]. Both, the prevalence of asthma and 
COPD is continuously increasing. The prevalence of asthma is particularly rising in the 
Western world due to increasing urbanization of communities and an increase in atopic 
sensitizations [3, 4]. In case of COPD, the rise is mainly due to an ageing population and an 
increase in smoke exposure [5].  In Swiss adults, prevalence of asthma and COPD was 
found to be around 7% [6, 7]. 
To date, asthma and COPD are not curable but treatable diseases of the respiratory system. 
Nevertheless, the burden of each disease among patients is high and patients may be 
frequently hospitalized due to exacerbation. This is defined as deterioration of the clinical 
status beyond day-to-day variability and associated with accelerated lung function decline 
[8], increased mortality [9] and reduced health-related quality of life (HRQoL) [10]. 
However, there are numerous reasons for the lack of disease control in asthma and COPD 
patients. For example, it is frequently associated with non-adherence to guidelines regarding 
treatment recommendation on the part of the healthcare provider [11, 12], as well as with 
poor inhalation technique [13] and/or non-adherence to the prescribed treatment plan by the 
patient [14, 15]. 
This is particularly cumbersome since effective treatment options are available for both 
asthma and COPD. In fact, depending on the COPD stage, only 18-66% of the patients are 
treated according to current guidelines [12, 16, 17] resulting in frequent over-treatment in 
patients with mild and under-treatment in patients with severe COPD [11]. Correct application 
of the inhaler device is a prerequisite in order for the medication to be fully effective. 
Nonetheless, up to 70-80 % of patients are unable to use their inhaler properly and do not 
suspect that they have problems with the application [18]. Moreover, sufficient long-term 
adherence to the prescribed medication plan is required to achieve full benefit [19, 20]. In 
patients with long-term therapy adherence tends to decline over time. In the Lung Health 
Study [21] examining self-reported inhaler use in patients with COPD over a period of two 
years, adherence to the prescribed treatment was 70% after four months of follow-up and 
decreased to 60% after 18 months of follow-up [21]. 
In this respect, the study of causes for non-adherence and the development of measures to 
increase, respectively, maintain adherence to therapies, in particular in chronic diseases is of 
major clinical importance. On the one hand, this cross-sectional analysis aims at presenting 
baseline data on compliance in accordance with current treatment guidelines (Global 
Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guidelines). On the other hand, it intends to provide baseline data on inhaler 
application and its impact on quality of life and symptom control in a typical population with 
chronic lung disease from the Adherence-Trial [22]. The longitudinal Adherence-Trial was 
designed to investigate adherence to inhaled medication over a period of six months in 
asthma and COPD patients with an innovative methodology in form of specific electronic 
devices. These are able to provide data about the timing of inhaler action. Moreover, the trial 
assessed the effect of an acoustic reminder and a close supervision on adherence, course of 
diseases and quality of life [22]. 
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METHODS 
STUDY DESIGN 
The Adherence-Trial was a single-blind randomized controlled trial. A detailed description of 
the study protocol has been described and published in a previous JMIR publication [22]. In 
brief, adherence to inhaled medication was analyzed over a six-month period in in- and 
outpatients with asthma and COPD who experienced at least one exacerbation within the 
previous year. Adherence was measured using electronic data capture devices, which save 
date and time of each inhalation device actuation and transfer these data daily via wireless-
connection to a web-based database. Patients were randomly assigned to either the 
intervention or the control group. The intervention group received audio reminder and 
support calls in case medication was not taken as prescribed or if rescue medication was 
used more frequently than pre-specified in the study protocol. During the study, participants 
were assessed every two months in form of clinical visits. 
MEASUREMENTS 
Sociodemographic Factors 
Sociodemographic variables such as age, gender, civil status and education level were 
obtained by a generic questionnaire at the baseline visit. Furthermore, smoking status, as 
well as pack years (py) and body mass index (BMI) were inquired during this visit. In 
addition, disease-related questions like allergies, number of exacerbations during the 
previous 12 months including treatments with antibiotics, treatment with systemic 
corticosteroids, emergency department attendance and hospitalizations were asked. 
Moreover, the current inhaled medication was recorded. 
Lung Function 
Spirometry was used to measure forced vital capacity (FVC) and forced expiratory volume in 
one second (FEV1) and was performed according to the guidelines of the American Thoracic 
Society [23]. The device EasyOne Pro (ndd Medizintechnik AG, Zürich, Switzerland) was 
used. 
Evaluation of Prescribed Inhaled Medication 
Asthma 
At baseline, the prescribed medication was recorded and compared with the 
recommendations of the GINA and GOLD guidelines 2014 [19, 20]. 
The participating asthma patients were classified into the corresponding treatment-step (see 
Multimedia Appendix 1) according to their prescribed inhaled medication at baseline. Asthma 
control was determined from the ACT (Asthma Control Test) score and set in relation to the 
inhaled medication. According to the GINA guidelines, patients were classified as “not on 
target” when asthma was either uncontrolled (ACT score 5-19, possibly under-treated 
asthma), or possibly over-treated, when the ACT score was 25 and a FEV1≥80% was 
predicted. Patients with well controlled asthma (ACT score 20-25) were considered to be 
appropriately treated and classified as “on target” according to the GINA guidelines (see 
Table 1) [19].  
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Table 1. Evaluation of prescribed medication by considering asthma control at baseline. 
a a step-up/step-down should only be considered after a trial period of 2-3 months. 
COPD 
In contrast to asthma, the treatment of COPD is performed according to the risk group the 
patient belongs to. The GOLD guidelines 2014 [20] established the risk groups A to D, 
considering lung function (GOLD severity stage I-IV) symptoms and the number of 
exacerbations in the previous 12 months. 
The participating COPD patients were classified into the respective risk groups taking into 
account the above-described factors. Then, the suggested therapy for each risk group (see 
Multimedia Appendix 2) was compared with the current treatment plan for every patient. 
Asthma- COPD- Overlap (ACO) 
GINA- and GOLD guidelines recommend to treat ACO with inhaled corticosteroids (ICS) and 
to add long acting beta2- agonist (LABA) and/or long acting muscarinic antagonist (LAMA), if 
necessary.  
Therapy plans in accordance with this guideline recommendation were rated as “on target 
with guidelines”, while those not in accordance with the guidelines were rated as “not on 
target with guidelines”. In addition, individual therapy plans were rated with regard to under, 
respectively over-treatment.  
Evaluation of the Device Application 
To detect false device application, each patient was asked to demonstrate the inhalation 
technique with all prescribed devices to the investigator by using a placebo device. As 
prescribed in the study protocol, correct use was assessed by using pre-defined checklists 
for each inhaler type based on user guidelines and instruction package inserts from the 
manufacturers. Inhaler technique was accepted as correct, when every step controlled in the 
checklist was performed accordingly. The technique was defined as wrong if one or more 
steps were done incorrectly. For each incorrect step, participants received a score of “0” 
whereas each correct application was valued as “1”. 
  
Asthma Control  Evaluation of Prescribed Medication  
Accordance with GINA- 
Guideline 
Very poorly controlled         
(ACT score 5-15) 
 
Possibly  under-treateda 
consider step-up 
Not on target 
Not well controlled 
(ACT score 16-19) 
 
Possibly under-treateda 
consider step-up 
Not on target 
Well controlled asthma 
(ACT Score 20-25) 
 
Medication appropriate On target 
Well controlled asthma with 
ACT-score of 25 and FEV1 ≥ 
80% predicted 
Possibly over-treateda 
consider step-down 
Not on target 
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Asthma Control  
The ACT questionnaire was applied in order to assess asthma control [24]. This is a 
validated questionnaire including five items referring to the previous four weeks. The ACT 
score ranges from 5 to 25. Values ranging between 5 and 15 indicate “very poor controlled 
asthma”, those from 16-19 “not well controlled asthma” and values varying from 20-25 signify 
“well controlled asthma” [24]. 
Impact of COPD Symptoms 
The health status of COPD patients was measured using the CAT (COPD Assessment Test). 
The CAT is a validated, disease-specific eight-item questionnaire on a sematic six-point 
differential scale. It is developed to measure the impact of the lung disease on the patients’ 
health status. Scores from 0-10, 11-20, 21-30 and 31-40 represent a “low”, “medium”, “high” 
and “very high” impact of the disease on a persons` health status [25]. 
STATISTICAL ANALYSIS 
Data were analyzed using the SPSS software package (version 23, IBM, Germany). 
Statistical significance was set at the 5% level. Data are presented as mean±standard 
deviation (SD) or number and percentage (%). To check the data for normal distribution, the 
Shapiro-Wilk test was used. For two unrelated parametric conditions, the independent t-test 
was applied, while for two unrelated non-parametric conditions, the Mann-Whitney test was 
calculated. In order to investigate the relationship between categorical variables, the 
Pearson’s chi-square test was applied. 
RESULTS 
A total of 169 asthma and COPD patients were recruited to participate in the study. Four 
patients withdrew after the training course. Therefore, a total of 165 patients (84 
interventions, 81 controls) were assessed at baseline (Figure 1). 
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Figure 1. Flow chart of study. 
PATIENTS’ CHARACTERISTICS  
Patients’ characteristics are presented in Table 2. Approximately 40% of the asthma patients 
had not well- or poorly controlled asthma at baseline, while less than 30% of the COPD 
patients showed a high- and very high impact of the disease on their health status. 
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Table 2. Characteristics of the 165 study participants at baseline. 
Variable Number(%) or Mean±SD 
 
All 
(n=165) 
Asthma 
(n=50) 
COPD 
(n=89) 
Asthma-
COPD-
overlap 
(n=26) 
     
Age 66.8±11.5 61.1±15.1 69.8±8.5 67.2±8.0 
Male 106(64.2) 23(46) 63(70.8) 20(76.9) 
Civil status 
    
   Unmarried 19(11.5) 7(14) 11(12.4) 1(3.8) 
   Married 104(63.0) 33(66) 51(57.3) 20(76.9) 
   Divorced/widowed 42(25.5) 10(20) 27(30.3) 5(19.2) 
Highest level of education at 
school 
    
   Primary school 27(16.4) 6(12) 18(20.2) 3(11.5) 
   Apprenticeship  97(58.8) 25(50) 55(61.8) 17(65.4) 
   Higher professional education  22(13.3) 7(14) 11(12.4) 4(15.4) 
   University–entrance 
   Diploma/Commercial college  
3(1.8) 3(6) 0(0) 0(0) 
   University /College of higher   
   education  
16(9.7) 9(18) 5(5.6) 2(7.7) 
Smoking status 
    
   Current smokers 32(19.4) 5(10) 24(27) 3(11.5) 
   Non-smokers 37(22.4) 28(56) 5(5.6) 4(15.4) 
   Ex-smokers  96(58.2) 17(34) 60(67.4) 19(73.1) 
Pack-years 35.0±34.3 8.0±14.3 58.5±33.0 32.3±35.5 
Body mass index [kg/m2] 27.2±5.1 26.9±3.9 26.9±5.6 28.5±5.3 
GOLD stage (n=115) 
    
   1 (FEV1>80% predicted) 8(6.9)  6(6.7) 2(7.7) 
   2 (FEV1 50-80% predicted) 47(40.9)  33(37.1) 14(53.8) 
   3 (FEV1 30-50% predicted) 46(40.0)  36 (40.4) 10(38.5) 
   4 (FEV1 <30% predicted)  14(12.2)  14(15.7) 0(0) 
Lung function parameters  
    
   FEV1 % predicted 59.9±24.5 80.0±19.9a 48.2±20.0 61.9±21.1b 
   FVC % predicted  90.2±19.0 98.7±17.7a 85.0±18.4 92.3±17.6b 
   FEV1/FVC ratio 51.9±16.7 66.3±12.3a 43.7±13.9 52.9±14.3b 
Asthma Control Test (n=76) 
    
   Sum score 19.5±4.5 20.7±3.8  17.15±5.0 
   Poorly controlled 15(19.7) 5(10)  10(38.5) 
   Not well-controlled 14(18.4) 8(16)  6(23.1) 
   Well controlled  47(61.9) 37(74)  10(38.5) 
COPD Assessment Test (n= 115) 
    
   Sum score 16.1±7  16±7 16.6±7.2 
   Low impact 25(21.8)  19(21.3) 6(23.1) 
   Medium impact  58(50.4)  46(51.7) 12(46.2) 
   High impact  29(25.2)  22(24.7) 7(26.9) 
   Very high impact  3(2.6)  2(2.2) 1(3.8) 
SGRQ (n=165) 
    
   Symptoms score 47.0±24.1 35.9±19.1 50.6±23.6 55.9±27.9 
   Activity score 48.6±22.3 34.5±21.0 54.9±20.2 54.4±20.0 
   Impact score 25.6±18.1 19.1±15.4 27.6±17.7 31.1±21.0 
   Total Score  36.1±18.1 26.6±15.4 39.6±17.2 42.3±19.6 
Known allergies 68(41.2) 33(66) 17(19.1) 18(69.2) 
Number of exacerbations in the 
past 12 months 
    
   1 92(55.8) 29(58) 50(56.2) 13(50) 
   2 28(17) 11(22) 15(16.9) 2(7.7) 
   3 21(12.7) 5(10) 10(11.2) 6(23.1) 
   >3 24(14.5) 5(10) 14(15.7) 5(19.2) 
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Number of antibiotic treatments in 
the past 12 months 
    
   Never 13(7.9) 8(16) 4(4.5) 1(3.8) 
   Once 91(55.2) 29(58) 50(56.2) 12(46.2) 
   2-3 times 43(26.1) 12(24) 23(25.8) 8(30.8) 
   More than 3 times 18(10.9) 1(2) 12(13.5) 5(19.2) 
Number of systemic corticosteroid 
treatments in the past 12 months 
    
   Never 77(46.7) 23(46) 44(49.4) 10(38.5) 
   Once 44(26.7) 12(24) 26(29.2) 6(23.1) 
   2-3 times 19(11.5) 7(14) 7(7.9) 5(19.2) 
   More than 3 times 25(15.2) 8(16) 12(13.5) 5(19.2) 
Number of emergency department 
attendance 
    
   Never 103(62.4) 40(80) 48(53.9) 15(57.7) 
   Once 44(26.7) 8(16) 28(31.5) 8(30.8) 
   2-3 times 16(9.7) 2(4) 11(12.4) 3(11.5) 
   More than 3 times 2(1.2) 0(0) 2(2.2) 0(0) 
Number of exacerbations with 
hospitalization in the past 12 
months  
    
   Never 97(58.8) 39(78) 43(48.3) 15(57.7) 
   Once 51(30.9) 7(14) 34(38.2) 10(38.5) 
   2-3 times 14(8.5) 4(8) 9(10.1) 1(3.8) 
   More than 3 times 3(1.8) 0(0) 3(3.4) 0(0) 
a  n=49; b  n=25 
Table 3. Characteristics of the prescribed medication of the 165 study participants at baseline. 
Variable Number (%) 
 
All 
(n=165) 
Asthma 
(n=50) 
COPD 
(n=89) 
Asthma-
COPD-
overlap 
(n=26) 
 
Medication (n=326) 
    
   LABA/ LAMA combinations 21(6.4) 1(0.3) 16(4.9) 4(1.2) 
   LABA/ICS combinations 116(35.5) 44(13.5) 50(15.3) 22(6.7) 
   LAMA 75(23) 5(1.5) 60(18.4) 10(3.1) 
   LABA 23(7) 3(0.9) 15(4.6) 5(1.5) 
   ICS 17(5.2) 8(2.5) 4(1.2) 5(1.5) 
   SAMA 2(0.6) 1(0.3) 1(0.3) 0(0) 
   SABA 68(20.9) 28(8.6) 31(9.5) 9(2.8) 
   SABA/SAMA combinations 4(1.2) 0(0) 1(0.3) 3(0.9) 
Number of inhaled medication at 
baseline  
    
   1  50(30.3) 17(34) 27(30.3) 6(23.1) 
   2 71(43) 26(52) 37(41.6) 8(30.8) 
   3 42(25.5) 7(14) 23(25.8) 12(46.2) 
   4 2(1.2)  0(0) 2(2.2) 0(0) 
Correct device application at 
baseline 
104(63) 32(64) 56(62.9) 16(61.5) 
Agreement of prescribed inhaled 
medication with guidelines   
    
   On target with guidelines   112(67.9) 33(66) 61(68.5) 18(69.2) 
   Under-treated 18(10.9) 13(26) 4(4.5) 1(3.8) 
   Over-treated 35(21.2) 4(8) 24(27) 7(26.9) 
LABA, Long acting beta2- agonist; LAMA, Long acting muscarinic antagonist; ICS, Inhaled corticosteroid; SAMA, 
Short acting beta2 - agonist; SAMA, Short acting muscarinic antagonist 
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A summary of the prescribed medication at baseline is illustrated in Table 3. The most 
frequently prescribed inhaled medications are combinations of LABA and ICS (35.5%), 
followed by LABA (23.0%) and SABA (20.9%). The majority of the participating patients had 
a dual therapy with a combination of two inhaled medication (44.8%) or a monotherapy with 
only one inhaled medication (29.7%). 
DEVICE APPLICATION CONSIDERING THE DIFFERENT INHALER TYPES  
Table 4 exemplifies the device application subdivided into the different inhaler types. Overall, 
correct inhalation technique ranged from 55% to 100% depending on the type of inhaler. The 
highest rate of incorrect device application was identified among patients using metered dose 
inhalers. Followed by those, who applied Turbohaler® as well as powder inhalation capsules 
such as HandiHaler® and Breezhaler®.  Patients who showed a better number of correct 
device application either used the Discus® or the newest powder device Ellipta®. When 
following the pre-defined checklists, which varied according to each inhaler type, there were 
some steps associated with a considerable number of repeated errors. For the metered dose 
inhaler, the two steps “shake the inhaler before actuation” and “coordination of actuation and 
inhalation” were performed incorrect by 27% (n=24) and 20% (n=17) of patients, 
respectively. In case of the Turbohaler® application, 30% (n=17) of the patients did not 
ensure that the device was held upright while charging in order to achieve correct dose 
loading. Furthermore, 9% (n=6) of the patients who applied the HandiHaler® did not “breath 
out completely before the inhalation” and did not “hold breath for at least 5 seconds after 
inhalation” (9%, n=6). Moreover, 10% (n=4) of the participants using Breezhaler® devices 
showed “multiple squeezing of the pushbutton to pierce the capsule”. It has to be noted that 
multiple piercing can cause the capsule to break into particles which requires full 
replacement. 
Table 4. Application of different inhaler devices. 
 
 
Device application 
Device n correct incorrect 
 
 Number (%) Number (%) 
 
   
Metered dose inhaler 84 46 (55%) 38 (45%) 
Discus® 31 27 (87%) 4   (13%) 
Turbohaler® 57 35 (61%) 22 (39%) 
HandiHaler® 66 52 (79%) 14 (21%) 
Breezhaler® 40 30 (75%) 10 (25%) 
Ellipta® 22 22 (100%) 0    (0%) 
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COMPARISON OF ACT AND CAT BETWEEN PATIENTS WITH CORRECT AND INCORRECT 
DEVICE APPLICATION AT BASELINE 
ACT and CAT sum scores between asthma, respectively COPD patients with correct and 
incorrect device application are shown in Figure 2 and 3. Regarding asthma control, no 
difference was observed between asthma patients with correct and incorrect device 
application (p=.99). In contrast, COPD patients with incorrect device application had a higher 
CAT sum score compared to those with a correct device application (p=.02). 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. Comparison of the mean ACT sum score 
with correct and incorrect device application at 
baseline (p=.99). ACT, Asthma Assessment Test. 
Figure 3. Comparison of the mean CAT sum score 
with correct and incorrect device application at 
baseline (p=.02). CAT, COPD Assessment Test. 
Figure 4. Mean comparison of the individual ACT 
questions in patients with correct and incorrect device 
application at baseline. ACT, Asthma Assessment 
Test.  
Figure 5. Mean comparison of the individual CAT 
questions in patients with correct and incorrect device 
application at baseline. CAT, COPD Assessment Test.  
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A subgroup analysis of the single ACT and CAT questions between patients with correct and 
incorrect device application is illustrated in Figure 4 and 5. There was no significant 
difference for all ACT-questions. However, for the CAT questions there was a significant 
difference in question one (p=.03) and question four (p=.02). 
Question one refers to the symptom “cough” while question four assesses the condition of 
being “breathless while walking up a hill or one flight of stairs”. 
COMPARISON OF LUNG FUNCTION PARAMETERS BETWEEN PATIENTS WITH CORRECT AND 
INCORRECT DEVICE APPLICATION AT BASELINE 
 
 
 
 
The comparison of the forced expiratory volume in one second (FEV1) (Figure 6) and the 
Tiffenaux (FEV1/FVC) (Figure 7) between asthma patients with correct and incorrect device 
application showed no difference. However, COPD patient who applied their devices 
correctly had a significantly better mean FEV1 at baseline compared to those who applied 
their devices incorrectly (p=.04). 
DISCUSSION 
MAIN FINDINGS 
This study revealed that 112 of the examined patients (68%) were treated on target taking 
into account the GINA and GOLD guidelines valid at the time of initiation of the study [19, 
20]. Overall, the application of metered dose inhalers and dry powder inhalers, such as 
Turbohalers® and Breezhaler®, showed more incorrect application by the patients while the 
devices such as Discus® and Ellipta® were used more correctly. In asthma patients, device 
application had no impact - neither on the ACT score nor on the lung function parameters. 
However, in COPD patients, incorrect device application had a negative impact on the CAT 
score. Furthermore, those who applied their devices correctly had a better forced expiratory 
volume in one second (FEV1). 
Figure 6. Comparison of the mean FEV1 % predicted 
in patients applying their devices corrects an incorrect. 
FEV1, forced expiratory volume in one second. 
Figure 7. Comparison of the mean FEV1/FVC % 
predicted in patients applying their devices correct and 
incorrect.  FEV1, forced expiratory volume in one 
second; FVC, forced vital capacity. 
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PATIENT CHARACTERISTICS 
In our study, baseline patient characteristics appeared to be comparable to previous studies 
with regard to the perception of disease. Thus, 40% of the asthma patients indicated that 
their disease was not well- or poorly controlled while 30% of the COPD patients stated a high 
or very high impact of the ailment on their health status. These results are comparable to 
prior studies by Guénette et al., where 48% of the patients reported an uncontrolled asthma 
[26] and by Dürr et al. where 34% of the patients had an uncontrolled asthma at baseline 
[27]. The mean CAT sum score was 16.7 in COPD patients at baseline, indicating a medium 
impact on health status – a value also observed in the PHARMACOP study, which examined 
the effectiveness of a pharmaceutical care programme in patients suffering from COPD [28]. 
When applying the 2014 GINA and GOLD guidelines, which take into account the symptoms 
and severity of the patients’ disease, around 70% of the patients appeared to be on target 
with regard to prescribed inhaled medication. Even though this is a relatively high rate of 
compliance with the guidelines valid at that time, this finding should be considered with 
caution. Since it can only be assumed that the patients were either on target or over-
/undertreated at the time of the baseline visit. In order to consider a change in form of an 
eventual step up or step down in the prescribed controller medication, the treating physicians 
should have tried the current therapy for at least three months as recommended by the 
guidelines. In addition, one does not know whether the patients take their medication 
according to the prescribed treatment plan or whether they are non-adherent. 
DEVICE APPLICATION AND DIFFERENT INHALER TYPES 
Correct handling of inhaler devices revealed to be very type-specific. Metered dose inhalers 
were more frequently applied in an incorrect way among the study population than dry 
powder inhalers. The same phenomenon was observed for dry powder inhalers like 
Turbohaler®, HandiHaler® and Breezhaler®. In contrast, the use of the dry powder inhaler 
Ellipta® was more often correct in the investigated sample. 
Frequent application errors identified in the study population were also confirmed by other 
studies. The results of the CRITIKAL study named the step of “coordination of actuation and 
inhalation” as one of the main errors in the application process of metered dose inhaler with 
an error rate of 37% [29]. 
Similar handling errors with the HandiHaler® were reported by Kiser et al.[30]. In this study, 
holding breath for a sufficient amount of time after inhalation was identified to be performed 
wrong in 40% of the cases. Even after an intervention, 30% of the HandiHaler® applications 
were performed incorrectly. 
Since the correct use of an inhaler by patients is directly related to the efficacy of the therapy, 
the selection of an adequate inhaler type taking into account the skills and preferences of the 
individual patient is an important aspect with regard to therapeutic success. This underlines 
the recommendation by Hodder et al., who stated that the satisfaction and preference of a 
patient for his inhaler device seems to have a potential impact on the adherence to therapy 
and consequently on the long-term outcomes of the disease [31]. 
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The good applicability of the Ellipta® device can certainly be explained by the fact, that the 
application itself is very simple. However, compared to the Discus®, there are not many 
differences regarding the application. Nevertheless, the correct handling of an Ellipta® device 
seems to be easier. It has to be noted that Ellipta® devices have just been introduced to the 
market. Therefore, the instructions for correct use provided by a doctor or pharmacist might 
be more detailed and informative compared to information related to older inhalation devices. 
At any rate, the baseline findings from the Adherence-Trial underline the importance of 
providing a comprehensive introduction to newly prescribed medications and a continuous 
educational training regarding recent developments in disease and therapy. This is 
particularly important in order to ensure that patients are continuously and actively involved 
in the treatment procedure [27]. Furthermore, these findings reconfirm the recommendation 
by the GINA and GOLD guidelines to regularly re-evaluate the correct device application to 
prevent faulty long-term device use [2, 18]. 
ACT AND CAT SCORES AND CORRECT/INCORRECT DEVICE APPLICATION AT BASELINE 
In asthma patients, the comparison of the ACT sum score as well as the individual ACT 
questions with the correct/ incorrect device application did not indicate any difference at 
baseline. This can be explained by the fact that all patients had to be in a stable condition 
and free of exacerbation for at least one month at the time of their inclusion into the study. 
Generally, asthma patients show none to very few symptoms during a stable phase of their 
disease. Moreover, all participants suffering from asthma had an ACT mean sum score of 
around 20, signifying a well-controlled disease condition at that point of time. 
However, one could assume that an observation of patients in an acute deterioration phase 
would indicate a difference when comparing the ACT sum score with the correct/ incorrect 
device application. Patients applying their inhalation device correctly would be expected to 
benefit more from the inhaled medication and would therefore show better symptom control 
compared to patients who use their device incorrectly. Price et al. conducted a real-life study 
with asthma patients, which showed that there is a difference between the type of inhaler 
used and the asthma disease outcome. Participants, who applied easier-to-use-inhalers and 
therefore had higher numbers of correct device applications showed better disease control 
[32]. 
A significant difference in the CAT sum score was found when comparing COPD patients 
with the correct and incorrect device application. Patients with an incorrect device application 
reported a higher impact of their disease on their health status. Subgroup analyses taking 
into account individual CAT questions revealed significant differences for symptoms like 
coughing and breathlessness. This may be explained by the fact that patients who apply the 
inhaler devices incorrectly are not expected to fully benefit from the effect of the prescribed 
medication, leading to more COPD symptoms like coughing and breathlessness during 
efforts. Furthermore, uncontrolled symptoms may adversely affect patients´ attitudes towards 
the medication. If they have the feeling that a therapy is not working, their adherence will be 
correspondingly low and the patient will no longer inhale the medication [31, 33, 34]. 
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LUNG FUNCTION PARAMETERS AND CORRECT/INCORRECT DEVICE APPLICATION AT 
BASELINE 
Interestingly, no differences were found for FEV1 in asthma patients at baseline when 
comparing correct versus incorrect device application. As mentioned before, the average 
FEV1 was very high at baseline providing a reasonable explanation for this finding. 
Nevertheless, this demonstrates once again that asthma patients may have no tangible 
impairment of their lung function during a stable phase and that even severely impaired lung 
function may be fully reversible after acute exacerbations. 
However, significantly higher FEV1 values were found in COPD patients who applied their 
devices correctly compared to those patients who did not. This finding underlines the results 
from previous studies revealing that correct and sustained use of inhaled medication is 
associated with a reduced loss of lung function and an improvement in quality of life [35-38]. 
LIMITATIONS 
The study is based on data that were determined during the baseline visit. We have no 
information about the course of the lung disease and medication adjustments before 
inclusion, since these were not recorded. Therefore, results should be interpreted with 
caution. 
Furthermore, since the patients had to be in a stable and exacerbation-free phase four week 
before inclusion, there is a bias regarding the health status of the study patients. Most 
patients described good health condition and good quality of life at baseline. This could lead 
to overestimation of the patient’s quality of life. 
CONCLUSION 
The baseline data from this study suggest that regular and comprehensive training of correct 
inhalation techniques is mandatory in patients with chronic lung disease in particular in 
patients with COPD. Patients applying their prescribed inhaled medication correctly seem to 
experience less impact of the disease on their health status and less limitation in their lung 
function. The findings from this study should encourage physicians and pharmacists to 
continuously provide instructions on correct inhalation technique and to re-evaluate the 
patient’s inhalation technique on a regular basis. By increasing the patient’s responsibility as 
well as integrating him or her into the treatment process, faulty use of inhalation devices can 
be prevented in the long-term with beneficial effects on signs, symptoms and progression of 
disease. 
However, in most of the investigated cases, physicians seemed to treat their patients 
correctly with regard to the current GINA and GOLD guidelines, when taking into account the 
symptoms and severity of the patient’s disease. Nonetheless, in order to make a meaningful 
statement, these results should be confirmed by further analyses that evaluate the disease 
control and the therapy adjustments during the months before study inclusion in more detail. 
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MULTIMEDIA APPENDIX 
 
Multimedia Appendix 1: Stepwise approach for asthma treatment, GINA guidelines 2014 (www.ginasthma.org). 
ICS, inhaled corticosteroids; LABA, long-acting beta2- agonist; OCS, oral corticosteroids; anti-IgE, anti-
immunoglobulin E; LTRA, leukotriene-receptor-antagonist. 
 
Multimedia Appendix 2: Pharmacologic treatment of the different risk groups of COPD, according to GOLD 
2014. SAMA, short acting anticholinergic; SABA, short acting β2-agonist; LAMA, long-acting anticholinergic; 
LABA, long-acting β2-agonist; ICS, inhaled corticosteroid; PDE-4 inhibitor, phosphodiesterase-4 inhibitor. 
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ABSTRACT  
Background and aim: Poor medication-adherence is common in chronic lung patients, 
resulting in reduced health-outcomes and increased healthcare-costs. The study aimed to 
investigate the impact of an acoustic reminder and a close monitoring on time to next 
exacerbation and adherence to inhaled medication in asthma and COPD patients. 
Methods: This single-blinded randomized controlled trial investigated asthma and COPD 
patients during six months. Exacerbations were recorded and adherence to inhaled 
medication was monitored using electronic data capture devices. Cox regression was used 
to determine intervention effect on time to exacerbation. 
Results: Of 149 eligible participants, 75 were assigned to intervention and 74 to the usual 
care. During a median follow-up of 6.19 months, 24.8% patients experienced an 
exacerbation. Intervention had no significant effect on time to exacerbation (HR 0.67, 95% CI 
0.36-1.33, p= .14). The intervention group had significantly more days with taking adherence 
of 80-100% regarding puff inhalers (81.6±14.2% vs. 60.1±30.3%, p<.001) and dry powder 
capsules (89.6±.9.8% vs. 80.2±21.3%, p=.01). Timing adherence in patients using puff 
inhalers was higher in the intervention group (68.9±25.0% vs. 50.6±32.5%, p<.001).  
Conclusion: Improved adherence is the benefits of regular automatic reminders and close 
supervision in patients with asthma and COPD.  
Trial registration: ClinicalTrials.gov: NCT02386722 
Keywords: asthma; chronic obstructive pulmonary disease; dry powder inhalers; medication 
adherence; metered dose inhalers; patient compliance; quality of life 
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INTRODUCTION 
Asthma bronchiale and chronic obstructive lung disease (COPD) represent a major 
economic burden [1].  Poor adherence to prescribed medication is common in patients with 
asthma and COPD, varying from 22-78% [2-5]. According to WHO, adherence is defined as 
“the extent to which a person’s behaviour corresponds with the agreed recommendations 
from a healthcare provider” [6]. Suboptimal or non-adherence to inhaled therapies has been 
shown to lead to increased rates of morbidity, healthcare expenditures, hospitalisations, and 
mortality. Moreover, quality of life (QoL) is reduced [7] and medical care is used more often 
due to deterioration of symptoms and recurrent exacerbations.  
Approximately 50-75% of healthcare expenditures related to COPD are caused by 
exacerbations [8], which often require hospital stays, physician visits, and additional 
medication. Moreover, exacerbations adversely affect patients’ quality of life, lung function, 
and mortality [9]. A recent Swiss study has shown that a comprehensive self-management 
asthma education programme can improve asthma control and patients’ outcomes [10, 11]. It 
is noteworthy that higher adherence rates have been associated with lower exacerbation 
rates in patients with asthma [12, 13] and COPD [14]. 
Thus, sufficient adherence to medication is a prerequisite for the achievement of therapeutic 
success in chronic diseases. Various interventions and strategies for improving adherence 
have been described. Interventions aiming at improving adherence were most successful 
when combining electronic devices and feedback on patients’ adherence behaviour [15]. 
However, intervention should be tailored to individual patient’s needs [16].  
Therefore, the aims of this study were to investigate the effect of a patient-tailored 
intervention on time to next exacerbation in patients with asthma and COPD with electronic 
monitoring of adherence. 
METHODS 
STUDY DESIGN  
The Adherence-Trial was a single-blinded randomized controlled trial conducted in 
Switzerland. The study protocol and baseline data have been described in detail elsewhere 
[17, 18]. In brief, 169 adult asthma and COPD patients were included and followed-up every 
two months for a total of six months. All patients had to have experienced at least one 
exacerbation within the previous year and remained on the treatment plan initiated by their 
general practitioner (GP). Written informed consent was obtained from every patient. 
Depending on the prescribed medication, participants were equipped with Smartinhaler 
devices for puff inhalers (Adherium Ltd., Auckback, New Zealand) and/or with Electronic 
Monitoring System (POEMS) consisting of a printed, self-adhesive polymer film affixed to a 
multidose punch card (Pharmis GmbH, Beinwil am See, Switzerland) that had been prefilled 
with dry powder capsules. Each inhalation device actuation of the Smartinhaler was saved 
with date and time and data were transferred daily to an online database via wireless internet 
connection. Every time the patient broke a loop for taking the capsules, date and time were 
recorded on a microchip, which was readout every two weeks when patients brought back 
the empty punch card. The study was approved by the local ethics committee (registry 
number: EK-269/13).  
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STUDY INTERVENTION  
Patients were randomly assigned in block size of two to the intervention or the control group. 
The intervention consisted of an audio-reminder, generated by an app (for Smartinhaler 
devices) an alarm clock (for POEMS), and directly transferred to the participants’ 
smartphones. Patients were allowed to choose the inhalation times themselves, depending 
on their GP’s treatment plan and their personal habits and daily routine. The reminder 
generated by the smartphone had to be quitted by the patients. Patients in the intervention 
group received support calls from the study pharmacist or study nurses when the use of 
rescue medication doubled or when the medication was not inhaled as prescribed for more 
than two consecutive days (only for puff inhalers). All participants also received a feedback 
on their intake pattern at each clinical visit, in form of a visualization graph.    
Patients assigned to the control group did not receive any reminder nor support regarding 
their intake of inhaled medication.  
MEASUREMENTS 
Sociodemographic variables such as age, gender and civil status were obtained by a generic 
questionnaire at the baseline visit. Smoking status, pack years (py) and body mass index 
(BMI) were assessed together with disease-related aspects such as allergies, number of 
exacerbations and hospitalisation during the previous 12 months. 
The primary outcome was “time to next asthma or COPD exacerbation”, defined as acute-
onset worsening of the patient’s condition beyond day-to-day variations requiring interaction 
with a healthcare provider [19]. Number of days between study begin and first exacerbation 
was defined as “time to next exacerbation”. 
The secondary outcome adherence was quantified by using Smartinhalers and POEMS 
devices [17], starting at the baseline visit and continuing until the end of the study. 
Smartinhalers were used for the inhalation with puff inhalers (metered dose inhalers, 
Turbohaler, Discus and Ellipta®). Once the devices were installed on the inhalers, patients 
were able to use their medication as usual. POEMS were used for inhalation with dry powder 
capsules.  
Objective adherence was quantified based on the following pre-specified criteria [20]:  
• Taking adherence = [number of puffs inhaled during 24 hours / number of puffs 
prescribed during 24 hours) x 100. Correct taking adherence was considered when 
taking adherence was between 80-100% (target range), based on previous studies 
[21].  
 
 
 
Part III: Objective Adherence and Health -Related Outcomes 
PhD Thesis 70  Claudia Gregoriano  
 
• Timing adherence = [number of correct dosing intervals during 24 hours / number of 
dosing intervals during 24 hours) x 100; correct dosing intervals was defined as an 
interval within a grace period of 25%, i.e between 
o 18-30 h for once daily dosing, 
o   9–15 h for twice daily dosing and 
o   6–10 h for three daily dosing.  
• Gaps = [number of days without inhalation during the study period / number of days 
of the study period] x 100. 
• Maximal gap length = longest period of time (in days) without inhalation. 
 
Health-related QoL was assessed using the St. George Respiratory Questionnaire (SGRQ) 
[22].  
SAMPLE SIZE CALCULATION 
Power calculation is based on "time to next exacerbation." We expected an assumed 
endpoint reduction of 60% (12/30), with 12% (8/70) of patients experiencing an exacerbation 
in the intervention group. Assuming a sample size of 70 participants for each study group, 
there is a power of 80% to detect a hazard ratio (HR) of 0.36 based on a 1-tailed test with a 
5%-significance level, since only a decrease of the exacerbation-risk is of interest and 
expected. For each study group 7 additional participants were added to account for dropouts. 
Therefore, a minimum of 154 participants were included in this study. 
STATISTICAL ANALYSIS 
Statistical analyses were performed by using the software R 3.1.3 [23] and the SPSS 
software package (version 23, IBM, Germany). Statistical significance was set at the 5% 
level. Data are presented as mean ± standard deviation (SD) or number and percentage (%). 
Differences between intervention and control group were assessed using t-test for 
continuous parametric variables, and the Mann-Whitney U-test for non-parametric variables. 
For categorical variables, the Pearson’s chi-square test was used. Time to next exacerbation 
was assessed using survival analyses. Median follow-up was calculated across censoring 
time (i.e. patients without exacerbation). Univariate analyses were performed based on the 
Cox proportional hazards model, using group as independent variable. Results are reported 
as HR with a corresponding confidence interval (CI) of 95% and p-value. Survival curves for 
the two groups were estimated and visualized by the Kaplan-Meier product limit method and 
compared using the log rank test.  
The robust nonparametric analysis of longitudinal data in factorial designs was conducted 
with the nparLD r package (function f1.ld.f1) to determine the effects of the factors time (1-
200 days) and group (control and intervention) on different measures of adherence in 
percent (taking, timing) [24]. Such methods are also robust with respect to outliners, missing 
data and for small sample sizes.  
There was no need to impute missing data (as originally planned in the study protocol). 
Subjects with more than 25% of missing data were excluded from the analysis [24]. 
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RESULTS 
Figure 1 provides an overview of the study’s patient flow. 
 
Figure 1. Flow chart of the study. 
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BASELINE CHARACTERISTICS  
Baseline characteristics are summarized in Table 1. Patients in the intervention group were 
younger, smoked less, and there were more asthmatics compared to the control group. 
Table 1. Baseline characteristics of the study patients (n=149). 
Variable  Number(%) or Mean±SD 
 Intervention (n=75) Control (n=74) p value 
    
Age 64.7±12.4 69.0±8.8 .01 
Male  46(61.3) 51(68.9) .33 
Civil status  
   
   Unmarried 7(9.3) 10(13.5) .47 
   Married 46(61.3) 48(64.9)  
   Divorced/widowed 22(29.3) 16(21.6)  
Diagnosed lung disease 
   
   Asthma 30(40) 16(21.6) .04 
   COPD 32(45.7) 45(60.8)  
   Asthma-COPD- overlap 13(17.3) 13(17.6)  
Smoking status  
   
   Current smoker 16(21.3) 12(16.2) .36 
   Non-smokers 19(25.3) 14(18.9)  
   Ex-smokers  40(53.3) 48(64.9)  
Pack-years 28.6±32.8 41.2±34.3 .01 
Allergic 35(46.7) 29(39.2) .36 
Body mass index [kg/m2] 26.5±4.2 28.±5.6 .12 
GOLD stage 
   
   1 (FEV1>80% predicted), mild 2(4.4)a 6(10.3)b .11 
   2 (FEV1 50-80% predicted), moderate 20(44.5)a 24(41.4)b  
   3 (FEV1 30-50% predicted), severe 19(42.2)a 21(36.2)b  
   4 (FEV1 <30% predicted), very severe 4(8.9)a 7(12.1)b  
FEV1 % predicted 63.9±25.0 56.5±23.5c .11 
FEV1/FVC % predicted 70.3±20.7 67.1±22.1c .35 
Number of inhaled medication 1.9±0.8 2.0±0.8 .54 
Number of co-morbidities  1.8±1.6 2.2±1.7 .13 
Number of exacerbations (last 12 months) 1.7±0.9 2.07±1.4 .18 
Number of exacerbations with 
hospitalisation (last 12 months) 
0.4±0.6 0.7±1.0 .25 
a
 n=45; b n=58; c n=72; FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity. 
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TIME TO NEXT EXACERBATION 
During the study, 37 (24.8%) patients experienced one or more exacerbations (endpoints); 
16 (21.3%) in the intervention, 21 (28.3%) in the control group. Median follow-up was 
6.19±0.52 months. After 200 days, the probability of no exacerbation was 78% [95% CI: 69% 
to 88%]. 
A longer average time to the next exacerbation was observed in the intervention compared to 
the control group (102 days [95% CI, 76 to 128] vs. 86 days [95% CI, 66 to 106], p=.19).  
 
Figure 2. Kaplan-Meier analysis for the comparison of the time to next exacerbation in patients in the 
intervention compared to the control group.  
 
Figure 2 shows the survival curves for intervention and control groups. Patients in the 
intervention group had a trend to lower exacerbation rate (one-sided p=.14) with a 0.67 times 
(33%) lower absolute risk of exacerbation (95% CI, 0.36 to 1.33) compared to patients in the 
control group.  
NUMBER OF EXACERBATION 
In total, there were 60 exacerbations during the observational period; 22 (36.7%) in the 
intervention group and 38 (63.3%) in the control group. Neither the number of exacerbations 
(0.3±0.6 [range: 0-3] vs. 0.5±1.0 [range: 0-5], p=.25) nor the 12 severe exacerbations 
requiring hospitalisation (0.08±0.3 [range: 0-2] vs. 0.08±0.4 [range: 0-3], p=.75) differed 
between the intervention and the control group. 
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OBJECTIVE ADHERENCE  
Three participants had to be excluded from the adherence analysis due to more than 25% 
missing adherence data. A mean of 7.17±9.72 (range: 0-51) support calls per patients were 
performed throughout the study period in the intervention group. 
Taking and Timing Adherence   
Data on taking and timing adherence are provided in Table 2. Calculations for puff inhalers 
were based on n=117 subjects and for dry powder capsules on n=90 subjects. The number 
of monitored days was comparable for puff inhalers and dry powder capsules use in both 
groups. 
The number of days in the pre-specified target range (80-100%) was significantly higher in 
patients assigned to the intervention compared to the control group. Timing adherence with 
puff inhalers was significantly higher in the intervention group. Despite a strong trend 
towards higher timing adherence with dry powder capsules, the difference between the 
two study groups failed to reach statistical significance.  
Table 2. Percentage of days in target range for taking and timing adherence during the 6 months 
observational period. 
a
 n=57;  b n=41; c n=60; d n=49 
 
Gaps 
Significantly less gaps for inhalation were observed in the intervention group with puff 
inhalers and dry powder capsules. Maximal gap length was significantly shorter for both, puff 
and dry powder capsules (Table 3). 16 patients assigned to the intervention with puff inhalers 
(16.4%) and four with dry powder capsules (4.1%) had no gaps during the whole 
observational period. For the control group there were 14 patients with puff inhalers (12.8%) 
and two patients with dry powder capsules (1.8%) identified without gaps.  
 
Variable Mean±SD 
 Intervention  Control p value 
Taking adherence   
  
 
   % of days in target range for puff inhalers 81.6±14.2a 60.1±30.3c 0.00006 
   % of days in target range for dry powder capsules  89.6±9.8b 80.2±21.3d 0.01 
Timing adherence 
  
 
   % of days with correct dosing interval for puff    
   inhalers 
68.9±25.0a 50.6±32.5c .0008 
   % of days with correct dosing interval for dry  
   powder capsules  
79.6±12.9b 71.7±22.0d 0.052 
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Table 3. Percentage of gaps and maximal gap length during the observational period. 
Variable Mean±SD 
 Intervention Control p value 
% gaps for puff inhalers  3.2±4.7a 11.7±18.6c .008  
% gaps for inhalation with dry powder capsules 4.6±4.4b 9.8±8.9d .009  
Maximal gap length for puff inhalers [days] 1.6±2.0a 11.6±25.6c .025  
Maximal gap length for dry powder capsules [days] 2.6±2.7b 5.9±5.2d .002  
a
 n=57;  b n=41; c n=60; d n=49 
 
Nonparametric test for time and group effects on adherence  
The results of the nonparametric analysis of longitudinal data in factorial experiments are 
shown in Table 4. Significant group effects were found for the taking adherence with puff 
inhalers and dry powder capsules, and for timing adherence.  
Table 4. Related group and time effects and group: time effect interaction for taking and timing 
adherence with puff inhalers and dry powder capsules. 
The group effect of the intervention group for taking and timing adherence is illustrated in 
Figure 3. The higher effect in the intervention group is maintained throughout the whole study 
period and it is more clearly distinguishable for the taking adherence with the puff inhalers 
(A) compared to the taking adherence with the dry powder capsules (B). Similar results were 
observed for the timing adherence (C-D). A higher effect can be observed for the intervention 
group with a major difference for timing adherence with puff inhalers (C). 
 
ANOVA-
type 
Statistic 
df p value Statistic df p value 
 Puff inhalers (N=117) Dry powder capsules (N=90) 
Taking adherence   
  
    
Group 6.3 1.0 .01 7.9 1.0 .005  
Time  1.2 39.5 .20 1.0 24.3 .40 
Group:Time 0.8 39.5 .80  1.1 24.3 .40 
Timing compliance  
  
 
   
Group 15.3 1.0 .00009 7.6 1.0 .006 
Time 1.1 36.14 .30 1.3 29.9 .10 
Group:Time 0.9 36.14 .60 1.2 29.9 .20 
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Figure 3. Group effect for the intervention and control group. Panel A: taking adherence with puff 
inhalers; Panel B: taking adherence with dry powder capsules. Panel C: timing adherence with puff 
inhalers; Panel D: timing adherence with dry powder capsules. 
HEALTH-RELATED QOL  
Significant differences between the intervention and control group were found at baseline 
regarding SGRQ total score and the subscale activity (Table 5). After six months, no 
significant differences in QoL were found between the two groups.  
Table 5. Changes in SGRQ scores after six months. 
Variable Symptoms Activity Impact Total Score 
Intervention 
    
   Baseline   
   (mean±SD) 45.7±21.5 45.2±19.3 21.8±14.6 32.5±14.7 
   6-month change    
   (95% CI) -0.59 (4.3 to -5.5) 0.2 (3.9 to -3.5) 1.3 (4.7 to -1.9) 0.7 (3.7 to -2.4) 
Control  
    
   Baseline  
   (mean±SD) 48.7±25.6 52.4±23.7 29.3±20.7 39.6±20.3 
   6-month change   
   (95% CI) -2.9 (2.8 to -8.8) 0.1 (3.8 to -3.5) -2.0 (1.2 to -5.2) -1.5 (1.5 to -4.5) 
p value 
    
   Baseline .44 .03 .05 .02 
   6 months change  .53 .70 .29 .77 
SD, Standard; CI, Confidence interval 
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DISCUSSION 
MAIN FINDINGS 
Our study demonstrated that an automatic and personal reminder potentially can delay the 
time to next exacerbation in patients with chronic lung diseases. The intervention was 
associated with a significant improvement in taking and timing adherence to inhaled 
medication. However, no impact on QoL was observed. 
EXACERBATIONS DURING STUDY PERIOD  
Only few exacerbations were observed during the study. The non-significant difference 
between groups can be explained by the fact that in general there were not enough events. 
Moreover, the follow-up period might have been too short. Clinical studies tend to include 
highly motivated participants causing a selection bias influencing health-outcomes in this 
study [25]. Mehuys et al. found no difference between the control and intervention group with 
respect to the occurrence of exacerbations after a six-months randomized, controlled trial 
[26]. In contrast, other studies comparing the effect of a treatment involving different active 
agents could detect a significant difference between the study groups regarding time to next 
exacerbation [27, 28]. However, these studies had more participants and a longer follow-up 
period compared to this study. Furthermore, a high adherence, as in our study, was found to 
be associated with reduced exacerbation rates in asthma [12, 13, 29] and COPD patients 
[14]. 
OBJECTIVE ADHERENCE  
Adherence to inhaled medication has been investigated in a variety of clinical trials. 
However, the majority of studies conducted with asthma and COPD patients used 
prescription refill adherence or self-report measurements to assess the inhaled medication 
adherence [30]. The most frequently used adherence measure methods in the last 10 years 
were self-report measurements (37.8%), prescription refill data (32.8%) and electronic 
monitoring (19.3%) [30].  
Patients assigned to the intervention group had a significantly better adherence. This shows 
that reminder can support patients to avoid forgetting the inhalation of the prescribed 
medication. This effect is partially confirmed by a systematic review which investigated the 
effect of electronic medication packaging devices on adherence. The review indicated an 
effect on adherence which varied from a decrease of 2.9% to an increase of 34.0% [31]. 
Tommelein et al. also confirmed the improvement of medication adherence after a 
pharmacist intervention in patients suffering from COPD [32].  
Furthermore, patients who inhaled with dry powder capsules had a higher percentage of 
days within the defined target range. This can be explained by the fact that medication 
available for dry powder capsules has a once-daily regimen and is thus easier to follow. This 
result is in line with other clinical trials which confirmed that taking and timing adherence 
were higher for once-daily regimens compared to two times or three times daily regimens 
[33]. The higher adherence rate obtained with electronic punch cards containing dry powder 
capsules might be explained by their simultaneous function as visual reminder [34].  
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Overall, taking and timing adherence were relatively high for puff inhalers and dry powder 
capsules, within both study groups. A positive selection bias might be present which can 
influence the adherence [25]. This could explain why participating patients already had a 
relatively high level of adherence and why it is therefore challenging to identify a positive 
effect on patients` health-outcomes [35, 36].  
HEALTH-RELATED QOL 
The intervention showed no effect on QoL. The follow-up period may have been too short to 
detect a clinical significance. Moreover, the mean SGRQ total score for all participating 
patients was very low, generally indicating a good health status of the patients. Therefore, 
the possibility to reach a clinically significant improvement is reduced. Similarly, other studies 
have observed comparable results when analysing health-related QoL after an intervention 
[32, 37]. However, studies that detected a significant improvement in QoL included a larger 
number of participants and all of them had a relatively poor QoL at baseline [38, 39]. The 
similar outcomes regarding QoL in both study groups can also be explained by a parallel 
effect of the study. Due to the fact that all participants received a general training course, 
experienced regular follow-up visits and had monitoring devices, it is likely that the control 
group also experienced a positive effect. Furthermore, wrong inhalation technique has been 
corrected in all patients due to ethical reasons. Hence, this could also have influenced the 
results. 
STRENGTHS AND LIMITATIONS 
To our knowledge, our study is the first to investigate a population affected by both, asthma 
and COPD. Moreover, only the adherence to a preselected medication class was 
investigated within these studies. The Adherence-Trial, however, imposed no restrictions 
regarding medication class. This can reflect a real life situation for the patients, since they do 
not experience any drug changes due to the study. Second, there was a real-time monitoring 
for the puff inhalers, which allowed a direct intervention without any delays. We acknowledge 
some limitation. First adherence monitoring was unblinded. All patients were aware of the 
fact that adherence was measured throughout the whole study using the electronic devices. 
This could have caused a “hawthorne effect” [40], which can elicit a bias in the data. Second, 
the relatively short follow-up period as well as the small sample size might explain the partly 
non-significant study results. Additionally, the study is difficult to compare due to the lack of 
studies with objective electronic monitoring methods.  
CONCLUSION  
This study demonstrates a trend towards a delay in exacerbation incidence and a reduced 
probability of experiencing an exacerbation. Regular, automatic and personal reminder had a 
beneficial effect on taking and timing adherence of inhaled medication in asthma and COPD 
patients. Positive effect of the intervention on QoL could not be detected. Further studies 
including a larger study population and extended follow-up period are needed to verify the 
results of the present study. 
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GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
Poor adherence to prescribed long-term medication poses a well-known challenge to the 
treatment of chronic diseases. Especially in asthma and COPD patients, uncontrolled 
disease is frequently associated with non-adherence to the prescribed treatment plan and 
poor inhalation technique. Consequences are considered to be poor health outcomes and 
increased health care utilization resulting in a substantial financial burden for the healthcare 
systems. In the Adherence-Trial on which this PhD-thesis is based, we were able to show 
that adherence to inhaled medication can be improved by a combination of two simple 
interventions. Furthermore, we observed a trend towards a prolonged time to next 
exacerbation within the intervention group. 
Therefore, the following conclusions can be drawn from this thesis: 
• At baseline, a large number of the participating asthma, COPD or asthma-COPD 
overlap patients were treated on target based on the GINA and the GOLD guidelines 
valid at the time of the patient’s inclusion into the Adherence-Trial. 
 
• Correct handling of inhaler devices was largely dependent on the device used. In the 
Adherence-Trial population, metered dose inhalers were applied more frequently in 
an incorrect way compared to dry powder inhalers. This particularly applies to the 
Ellipta® device, which has just recently been introduced to the market and which 
showed a very good applicability. 
 
• A correct inhalation technique of the prescribed medication seemed to have a positive 
impact on the health status and the lung function of COPD patients. This was 
achieved by a comprehensive training of correct inhalation technique.  
 
• Regular, automatic and personal reminders seem to have caused a significant 
improvement in taking and timing adherence with regard to the inhalation with puff 
inhalers and dry powder capsules. Moreover, reminders can help to avoid forgetting 
the inhalation of the prescribed medication. Patients who experienced support in their 
adherence had significantly fewer days without inhalation and fewer gaps over 
several consecutive days compared to patients receiving no support. 
 
• Regular, automatic and personal reminders, led to a substantial improvement in 
patients’ adherence to inhaled medication. However, this was not associated with an 
improvement in health-related quality of life in patients with chronic airway diseases. 
 
• Higher adherence to the prescribed medication plan was not only associated with a 
trend towards longer time to next exacerbation but also with a reduced risk of 
experiencing an exacerbation.  
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Based on the results of the Adherence-Trial, the following recommendations can be made for 
clinical practice: 
• Since the correct use of an inhaler by patients is directly associated with the efficacy 
of the therapy, the choice of the inhalation devices represents an important step in 
order to achieve therapeutic success. The selection of the device type should take 
into account the patients’ skills and preferences and should be individualized 
according to the patient’s need whenever possible. 
 
• The prescription of a new inhaled medication or a change in device should always be 
accompanied by a comprehensive educational effort on its use from the side of the 
responsible physician and/or pharmacist. Furthermore, a regular re-evaluation of the 
patient’s inhalation technique should be ensured to prevent faulty long-term device 
use. 
 
• The introduction of regular adherence monitoring as a routine tool in everyday clinical 
practice continues to be challenging due to the time-consuming data analysis 
process. However, the introduction of a daily reminder for the prescribed inhalation 
times and a visual aid for the dry powder capsules could be a good approach to 
achieve higher adherence. 
 
Though the Adherence-Trial formally failed to reach its primary endpoint, there was a trend 
towards an increased time to next exacerbation of asthma respectively COPD. This finding 
certainly needs to be confirmed by further research, involving a higher number of study 
participants and a longer follow-up period in order to verify clinically significant changes in 
this important health-related outcomes. The lack of a significant difference in the primary 
endpoint between the intervention and the control group may be due to the fact that patients 
in the latter group also underwent adherence monitoring, which is not equal to usual care. 
Nevertheless, without monitoring the comparison between groups and the interpretation of 
the study results with regard to differences in taking and timing adherence would have been 
substantially limited.  
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